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Уходят наши матери от нас, 
уходят потихонечку, 
на цыпочках, 
а мы спокойно спим, 
едой насытившись, 
не замечая этот страшный час. 
Уходят матери от нас не сразу, 
нет — 
нам это только кажется, что сразу. 
Они уходят медленно и странно 
шагами маленькими по ступеням лет. 
… 
Все удаляются они, 
все удаляются. 
К ним тянемся, 
очнувшись ото сна, 
но руки вдруг о воздух ударяются — 
в нем выросла стеклянная стена! 
Мы опоздали. 
Пробил страшный час. 
Глядим мы со слезами потаенными, 
как тихими суровыми колоннами 
уходят наши матери от нас… 
 
 
Евгений Евтушенко, 1960 г. 
 
Our mothers depart from us, 
gently depart 
On tiptoe, 
but we sleep soundly, 
stuffed with food, 
and fail to notice this dread hour. 
Our mothers do not leave us suddenly, 
no — 
it only seems so ‘sudden’. 
Slowly they depart, and strangely, 
with short steps down the stairs of years. 
… 
They withdraw ever further, 
withdraw even further. 
Roused from sleep, 
we stretch toward them, 
but our hands suddenly beat the air — 
a wall of glass has grown up there! 
We were too late. 
The dread hour had struck, 
Suppressing tears, we watch our mothers, 
in columns quiet and austere, 
departing from us. 
 
By Yevgeny Yevtushenko, 1960. Translated 
by Albert Todd and James Ragan. 
  
POPULAR SCIENCE SUMMARY OF THE THESIS 
Chlamydia infection is one of the most common bacterial infections transmitted via 
sexual contact. Every year 127 million people are infected with chlamydia in the world. 
Chlamydia is very common among adolescents and young adults. What is also striking is that 
the infection often has no symptoms and infected people could be unaware of it. If an infection 
is untreated, it can lead to serious complications in the organs involved in sexual reproduction, 
causing chronic pain and possible difficulties to conceive later in life. Researchers have 
identified several factors with an increased risk to be infected with chlamydia infection, such 
as younger age, sexual contact with casual partners without using condoms. Therefore testing 
for chlamydia after having unprotected sex is important, even if one does not have symptoms. 
Testing, treatment, and identification of sexual partners are important components to control 
the spread of chlamydia in the population.  
It is essential to follow the trends of chlamydia in order to monitor the changes, interpret 
them, and adjust control measures, if necessary. Taking into consideration testing intensity in 
the population allows a better understanding of the number of diagnosed chlamydia cases. 
Testing, which is widely accessible in Sweden, as well as following treatment and sexual 
partner identification, can affect chlamydia presence in the population. Therefore, knowledge 
on chlamydia occurrence in the population is important for planning control measures and 
possible prevention campaigns. 
In this thesis, we focus on a better understanding of behaviours associated with 
chlamydia and repeated testing, as well as the distribution of infection over time and in the 
population. In study I, we found that high-risk behaviours (e.g., more than 6 sexual partners, 
alcohol use before a sexual encounter, being young) are associated with chlamydia infections. 
In study II, individuals characterised of several high-risk behaviours were tested more often 
repeatedly for chlamydia, suggesting that they have followed public health messages to be 
tested if they consider themselves at risk for chlamydia. In study III, we concluded that 
chlamydia cases reported during the past 10 years were more likely to mirror the real situation 
with chlamydia in the population since we capture in our surveillance system only a part of 
infections without symptoms. Moreover, testing volumes play an important role in interpreting 
trends of chlamydia infection. Additionally, in study IV, for the first time in Sweden, we 
estimated the occurrence level of chlamydia infection in the population of 15-29 year olds, and 
it was comparable to other high-income countries.  
In summary, we gained a better understanding of risk factors for chlamydia infection and 
repeated testing, chlamydia trends over time, and distribution in the population, which will help 
to assess and plan future control measures in Sweden.  
  
 
 
ABSTRACT 
Chlamydia trachomatis (chlamydia) infection is the most common bacterial sexually 
transmitted infection (STI), with an estimated 127 million new cases occurring every year 
worldwide. Due to the asymptomatic nature of the infection, individuals may carry it for a long 
time and transmit without knowing about it. Untreated chlamydia may lead to serious sequelae 
of the reproductive tract, causing pelvic inflammatory disease, chronic pain, ectopic pregnancy, 
and tubal factor infertility. Thus, early detection of infected individuals via testing 
(opportunistic testing), treatment, and partner notification may prevent further transmission of 
infection.  
In this thesis, we aimed to gain an extended understanding of chlamydia epidemiology 
at an individual and population-based level. The thesis is based on the data from a cohort study 
in the urban STI clinic, as well as chlamydia cases and tests reported to the national infectious 
diseases register SmiNet-2 at the Public Health Agency of Sweden. We employed various 
methodologies to answer our study questions. In Studies I and II, we used data from a cohort 
study, which we analysed cross-sectionally. We found that being 20-24 years old, having 6 or 
more sexual partners during the previous 12 months, using alcohol before sex, reporting all 
type of sexual activities during the last sexual contact, and testing due to partner notification 
were independently statistically significantly associated with increased risk to test positive for 
chlamydia. Furthermore, we identified four groups (latent classes) of behaviour patterns among 
men and three among women in our cohort. The classes characterized by high-risk sexual 
behaviour were associated with statistically significantly increased 2-fold odds for lifetime 
repeated testing for chlamydia among men and women. Women in the high-risk behaviour 
class had also 2-fold increased odds to test repeatedly during the previous 12 months. This 
indicates that individuals at higher risk for chlamydia acquisition had adhered to the public 
health messages to test if at risk for infection. In Study III, we used time series analysis to 
explore how chlamydia trends changed over time, by comparing two periods: before and after 
the discovery of a new variant of Chlamydia trachomatis in Sweden. We analysed data 
nationally and by two types of counties, grouped according to their ability to identify new 
variant at the time of discovery. We also adjusted chlamydia trends to the testing intensity. We 
found that chlamydia trends were increasing since the mid-1990s up to 2004, as was testing, 
suggesting that chlamydia notification trends were driven by the testing. On the other hand, 
during 2009-2018 chlamydia trends were decreasing, despite increasing testing intensity, 
suggesting that chlamydia cases were not driven by testing, and most probably, these trends 
reflect true chlamydia incidence rates in the population. In Study IV, we continued to explore 
the reason for the decreasing chlamydia trends during 2009-2018 by estimating chlamydia 
prevalence via mathematical modelling. Indeed, we estimated a decrease in chlamydia 
prevalence among 15-29 year old men and women during this period, which supports our 
hypothesis.  
In conclusion, the risk factors independently associated with chlamydia diagnosis are in 
line with previous studies. Furthermore, our results suggest that individuals in the high-risk 
sexual behaviour latent classes are more likely to test repeatedly for chlamydia, suggesting 
absorption of public health messages. Moreover, chlamydia trends were not driven by testing 
intensity during 2009-2018, suggesting a true decrease in chlamydia incidence rates in the 
population. By estimating the decrease in chlamydia prevalence during this period, we were 
able to support the hypothesis on the reason for observed declining chlamydia trends. 
Prevention work should be continued to reach asymptomatic individuals by testing and 
prevention messages. Further studies should investigate the role of other components of 
chlamydia control strategy on chlamydia trends to disentangle their input and plan for possible 
future alterations.  
 
Keywords: chlamydia infection, epidemiology, risk factors, incidence rate, opportunistic 
testing, repeated testing, prevalence, mathematical modelling, time series analysis, latent class 
analysis, regression analysis 
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 1 
1 INTRODUCTION 
 
Chlamydia trachomatis infection (chlamydia) is one of the most common curable 
bacterial sexually transmitted infections (STIs), with an estimated 131 million new cases 
worldwide among populations aged 15–49 years in 2012 (1). Chlamydia is an important public 
health problem not only because of its high case rates and because of the potential to cause 
reproductive sequelae in both men and women (2, 3) but also due to the broader aspect of being 
a part of the sexual health well-being. Therefore, countries are urged to work towards “ensuring 
universal access to sexual and reproductive health care services, provide family planning, 
information and education, and integrate reproductive health into national strategies and 
programmes” as stated by the United Nations (UN) Sustainable Development Goal (SDG) 3 
sub-goal 3.7 (4). In Sweden, sexual well-being, where definition includes also the absence of 
STIs, is part of the national strategy for sexual and reproductive health and rights (SRHR) (5).  
Sweden has a long tradition of epidemiological and microbiological surveillance of 
chlamydia infection. To control chlamydia, several measures are in place with the goal to 
identify and treat cases of chlamydia and prevent sequelae in the population. As part of my 
work with epidemiological surveillance at the Public Health Agency of Sweden, data analysis 
and interpretation is a daily task. However, sometimes interpretation is not straightforward and 
requires additional data. Hereby several hypotheses formed the basis for the studies in this 
thesis. This thesis aims to provide improved knowledge on chlamydia epidemiology in Sweden 
and adds evidence to a pool of chlamydia research.  
  
 
2 
2 BACKGROUND 
2.1.1 Epidemiology  
2.1.1.1 Chlamydia trachomatis pathogen and clinical manifestations 
Chlamydia infection is caused by Chlamydia trachomatis, which is an obligate 
intracellular gram-negative bacterium with an incubation time between 1-3 weeks (6). 
Chlamydia trachomatis can cause a range of clinical manifestations, which are linked to 19 
serovars and variants (7). Serovars A–C are responsible for hyperendemic blinding trachoma 
and are prevalent in tropic countries (6). Urogenital chlamydia caused by the serovars D–K can 
manifest as urethritis, cervicitis, and proctitis, characterized by pain and discharge, and is most 
common in heterosexual populations. The most common serovars found among men who have 
sex with men (MSM) are D, G, and J (8), while serovars E and D are more often reported in 
heterosexual populations (9, 10). Another less common clinical presentation of these serovars 
is neonatal conjunctivitis and neonatal pneumonia. Finally, serovars L1–L3 cause 
Lymphogranuloma venereum, which re-emerged in 2003 in the Netherlands and later 
elsewhere (11, 12), were exclusively reported in MSM (13). In this thesis we are focusing on 
the population, where the most of chlamydia transmission is ongoing, that is the heterosexual 
population (which is defined below). 
Chlamydia infections are often asymptomatic: about 75% of women and 50% of men do 
not present any symptoms (6). In another study, it was estimated that 11% of chlamydia 
infections in men and 6% in women become symptomatic (14). 
Apart most common urogenital presentation of chlamydia, the prevalence of extragenital 
chlamydia infection is not uncommon, especially in MSM. In a recent review, extragenital 
chlamydia in women a median of 8.7% was reported for rectal infection and a median of 1.7% 
for pharyngeal chlamydia (15). This study, which is based mostly on the review of the studies 
carried out in STI clinics, also reported that most of the chlamydia infections were 
asymptomatic in women (36–100% of rectal and 100% of pharyngeal chlamydia) (15). Among 
men who have sex with women, a median prevalence of 7.7% was reported for rectal and 1.6% 
for pharyngeal chlamydia infections (15). However, it is noteworthy that some women who 
test positive for rectal chlamydia deny having had anal sex. This has been suggested as possible 
due to the autoinoculation of the rectum from vaginal secretions (16, 17). Meanwhile, rectal 
chlamydia identified among men who have sex with women who did not report anal sex, could 
also be explained by inaccurate reporting of sexual contacts with other men (15) or by possible 
inoculation during sexual practices with women (e.g., cunnilingus) (18). 
Several studies have also reported Chlamydia trachomatis co-infection with other 
sexually transmitted pathogens, such as human papillomavirus, Mycoplasma genitalium, and 
Neisseria gonorrhoeae (19-24), with prevalence depending on the setting, the country, and so 
called “key populations” (25). Studies have also reported that Chlamydia trachomatis was 
independently (26) in co-infection with human papillomavirus (20) associated with cervical 
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intraepithelial neoplasia. An important finding also reported in the literature is that the presence 
of Chlamydia trachomatis can facilitate transmission of HIV through the inflammation in the 
tissues (27-29). 
 
2.1.1.2 Transmission routes 
In this thesis, we are not describing the population based on their sexual identity, but their 
sexual orientation (30). Sexually acquired chlamydia can be transmitted via oral, vaginal, or 
anal sexual contacts and clinical presentations therefore reflect the sexual contact practices. 
Based on that and the biological sex of the person, possible routes of the transmission are 
categorised as follows: heterosexual transmission (sexual contacts between persons of opposite 
sex), homosexual transmission (sexual contact between persons of the same sex, specifically 
MSM) and bisexual transmission (sexual contact with persons of both sexes). Heterosexual 
transmission is the predominant route of transmission reported in the literature, with 86% 
transmitted heterosexually and 5% transmitted in MSM (31). Because chlamydia infection is 
reported elsewhere and in Sweden predominantly heterosexually transmitted (32), the focus in 
this thesis is on this population, with only some occasional remarks on other populations at risk 
for chlamydia. Chlamydia infection can be transmitted from mother to newborn child during 
vaginal delivery; however, this is a rare transmission route due to prenatal screening in some 
countries (33). While in Sweden no official recommendations exist, pregnant women are 
offered testing for chlamydia around week 10-12 of pregnancy, however the screening is done 
at varying degrees in the country (34). 
Transmission probability for chlamydia varies depending on the type of sexual contact, 
number of sexual acts and partnership length. It has been estimated that transmission 
probability was 2.0% (interquartile range: 1.7–2.2%) per vaginal sex act and 5.8% (interquartile 
range: 3.0–8.3%) per anal sex act, both from male-to-female and female-to-male (17). Another 
study estimated transmission probability of 32.1% (95% credibility interval (CrI) 18.4–55.9%) 
from male to female and transmission probability of 21.4% (95%CrI 5.1–67.0%) from female 
to male per partnership (35), which was similar to the earlier estimates (36). 
 
2.1.1.3 Geographic distribution 
Based on various methodologies, the number of new chlamydia cases has been estimated 
since 1995 at which point it was 89 million cases among adults annually (1, 37). Globally in 
2016, there were an estimated 127.2 million (95% UI: 95.1–165.9) new chlamydia cases (37). 
The majority of new chlamydia infections were estimated in upper-middle-income countries 
(47%) and lower-middle-income countries (31%), followed by low-income countries (13%) 
and high-income countries (8%) (37). In the European Union and European Economic Area 
(EU/EEA), overall chlamydia trends stabilized during 2009-2018, with 146 cases per 100 000 
reported in 2018 (31). 
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The highest estimated prevalence in the World Health Organization (WHO) regions in 
2016 was reported among women in the Region of the Americas (7.0%), followed by the 
African Region (5.0%) and the Western Pacific Region (4.3%) (Table 1). Among men in 2016, 
the highest chlamydia prevalence was estimated in the African region (4.0%), followed by the 
Region of the Americas (3.7%) and the Western Pacific Region (3.4%) 
 
Table 1. WHO regional prevalence estimates (with 95% uncertainty intervals) of 
chlamydia 2012 and 2016 by sex (source: reference (37), reproduced with permission). 
 
 
2.1.1.4 Time trends 
Systematically collected data on chlamydia cases have become available since the late 
1980s or the early 1990s, with introduction of surveillance systems elsewhere (38). From late 
1980s chlamydia notification rates have decreased in some of the countries (32, 39, 40), while 
increasing in others (41). The reason behind the decrease was suggested by the change in sexual 
behaviour as a result of the HIV/AIDS campaigns in place at the time (40). The notification 
rates increased from 55 cases in 1990 to 139 cases per 100 000 in 2000 in EU/EEA (Figure 1) 
(38). The rates in EU/EEA more than doubled between the years 2000 and 2009, reaching 338 
cases per 100 000 population in 2009. However, due to the incompleteness of the reported data 
and differences in the type of surveillance systems, as well as the differences in the control 
measures, these rates are based on 8 countries reporting consistently (Denmark, Estonia, 
Finland, Iceland, Ireland, Latvia, Sweden and the UK) (38). Similar increasing trends during 
that time were reported from the USA, Canada and Australia (41-43). The reason for the 
increase in chlamydia rates during that time were possibly the introduction of more sensitive 
diagnostic methods and possibly increased chlamydia prevalence in the population, as well as 
an alteration of target groups for testing for high-prevalence chlamydia (44-47).  
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Figure 1. Number of notified chlamydia cases per 100 000 population in EU/EEA 
Member States that have reported consistently (n=8), 1995-2009 (source: reference (38), 
reproduced with permission). 
 
Furthermore, notification trends in EU/EEA between 2008 and 2017 stayed relatively 
stable, with 198 cases in 2008 and 206 cases per 100 000 in 2017 (Figure 2) (48). Reporting 
have improved since 2008, thus rates since this year are based on 17 countries reporting 
consistently. Although, the overall chlamydia trend remained stable in EU/EEA during 2008-
2017, rates of chlamydia continued to increase in Denmark, Finland and Norway, as well as in 
North America (48-50). Nevertheless, notification rates should be interpreted with caution as 
reporting of the cases could be incomplete, the quality of the laboratory tests may vary over 
time and screening programmes may cover diverse populations (51). 
 
Figure 2. Number of notified chlamydia cases per 100 000 population in EU/EEA 
Member States that have reported consistently (n=17), 2008-2017 (source: reference (48), 
reproduced with permission). 
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In Sweden, chlamydia notification rates started to decrease just the after introduction of 
the surveillance system in 1988; between 1990 and 1994 from 311 cases to 155 cases per 
100 000 (Figure 3). Between 1994 and 1997, a plateau was noted with the lowest recorded 
notification rates. Between 1998 and 2005, chlamydia rates increased in Sweden by 113%. In 
2006, a new genetic variant of Chlamydia trachomatis (nvCT, new Swedish variant of C. 
trachomatis) was discovered with a deletion in the cryptic plasmid DNA, which was a target 
for commonly used diagnostic tests in Sweden at the time (52). Thirteen out of 21 counties 
(62%) in Sweden used the diagnostic tests that were unable to detect nvCT, which led to missed 
diagnoses possibly as early as in 2003 (53, 54). The proportion of nvCT among detected cases 
varied from 10% to 65% between Swedish counties in late 2006 and early 2007 (55). The 
deficient laboratory tests were replaced with adequate assays able to detect nvCT, which 
allowed detecting accumulated undiagnosed nvCT cases, leading to the increase in the national 
notification rates of chlamydia in 2007-2008 (56). In addition, the testing for chlamydia and 
partner notifications were reinforced as well. As a result, the proportion of nvCT among all 
chlamydia cases dropping to 5% in all counties towards 2015 (57). Notably, only sporadic or 
no cases of Swedish nvCT were reported elsewhere in the world (58-63). Following the years 
after the discovery of nvCT, the chlamydia rates dropped in Sweden between 2009 and 2020 
from 406 cases to 321 cases per 100 000 (Figure 3). Recently, another new variant of 
C.trachomatis was reported to emerge in Finland in 2019 (64). These incidents urge countries 
to be vigilant in monitoring chlamydia trends and assessing the quality of the laboratory 
diagnostic tests. 
 
 
Figure 3. Number of reported chlamydia cases per 100 000 population in Sweden, 1988-
2020 (Source: Public Health Agency of Sweden. The data for 2020 is preliminary as per 
January 14, 2021). 
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Epidemic phases for sexually transmitted infections were proposed to describe long-term 
trends of chlamydia (65, 66). As proposed, the first phase starts with the introduction of 
chlamydia to the susceptible populations, effective transmission through the sexual networks 
and eventual establishment in the general population. Next, the hyperendemic phase is 
characterised by rising rates of infection and introduction of the control measures to reduce 
incidence and prevalence. After control measures to reduce the transmission probability of 
chlamydia or its duration of infectiousness are in place, chlamydia trends are expected to fall 
as prevalence declines and as a result, the decline phase begins (66).  
 
2.1.1.5 Demographics 
Globally, the estimated number of new cases in 2016 was 34 cases per 1 000 women 
(95% UI: 25–45) and 33 per 1 000 men (95% UI: 21–48) (37). For instance, in the USA, around 
97% and 94% of all chlamydia cases were reported in 2018 in the age group 15-44 years in 
women and men respectively, with male-to-female ratio of 0.7 (49). Similarly in EU/EEA, the 
majority of the cases are reported in the age group 15–24 years (62% of cases with known age), 
followed by the age group 25-34 years (27% of the cases), with male-to-female ratio of 0.8 
(31). Women are overrepresented in the number of chlamydia cases most likely due to health-
care seeking behaviour, e.g., more frequent contacts with health care services due to routine 
visits with gynaecologists and family planning counselling. In Sweden, 85% of chlamydia 
cases are reported in the individuals aged 15-29 year. The highest reporting rates among women 
are in the age groups 15-19 and 20-24 years (Figure 4). Among men, the highest reporting 
rates are notified in the age group 20-24 and 25-29 years. Overall, 57% of all notified cases 
were reported among women between 1992 and 2019 in Sweden. The male-to-female ratio of 
0.8 has been unchanged since 2001 (32).  
 
Figure 4. Number of notified chlamydia cases per 100 000 population in Sweden by age 
groups and sex, 1997-2020 (source: Public Health Agency of Sweden. The data for 2020 
is preliminary as per January 14, 2021). 
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2.1.1.6 Clearance of chlamydia infection 
Chlamydia infection can clear spontaneously without treatment as a result of the immune 
response (67). The duration of untreated chlamydia infection is an important factor to account 
for when considering measures to control chlamydia in the population. Studies among women 
reported that asymptomatic chlamydia has cleared naturally in approximately 50% of the 
women at the 1 year follow-up (68, 69), in 82% of the women the infection cleared after 2 years 
and 94% of the infection had cleared after 4 years of follow-up (68). It was also reported that 
women with persisting infection at enrolment had a five times higher reinfection rate at the 
follow-up visit (OR=5.2, 95%CI: 1.2–33.0); as compared to women with spontaneous 
resolution at enrolment (the time when patients who had tested positive for chlamydia returned 
for treatment) (70). The bacterial load was reported to be stable or decreasing during the first 
month after a positive chlamydia test in the majority (90%) of the patients at STI clinics (71). 
In the modelling study it was estimated that duration of asymptomatic infection in women was 
1.36 years (95%CI: 1.13-1.63 years) (72). In a recent study at STI clinics, it was reported that 
women infected with chlamydia at a single anatomic site cleared a viable chlamydia infection 
at a higher rate (follow-up of median 9 days) than women concurrently diagnosed with rectal 
chlamydia (73). Studies in men reported higher proportion of persistent infections and slower 
clearance than in women (74, 75). The mean infection duration time in men was estimated to 
be 2.84 (95%CrI: 0.87-18.79) years compared to 1.35 (95%CrI: 1.13-1.63) years in women 
(74). In a population of STI clinics, between 7% and 57% of the chlamydia infections cleared 
between testing and treatment time (median of 10 days), depending on anatomical site sample 
(urogenital, anorectal, pharyngeal) and subgroups of population (heterosexual vs MSM) (76). 
In the same study authors reported that lower bacterial load at the initial testing was associated 
with clearance in all types of samples (76).  
 
2.1.1.7 Risk factors for infection  
A lot of research has been done on factors associated with chlamydia acquisition over 
the past 30 years. Studies that covered different populations, such as health care clinic patients, 
the general population, and users of a website for ordering home-based chlamydia sampling 
kits, pregnant women and military recruits were hence subject to different types of biases. Well-
established independent factors associated with chlamydia are: younger age at the first 
intercourse, age under 25 years, multiple sexual partners within during the previous year and 
during lifetime as well as recent change of partner, inconsistent condom use with casual or new 
partners and the occurrence of previous STIs (77-84). Some studies also identified relationship 
between socio-economic status and chlamydia (85), however results are inconclusive and it 
was suggested that the neighbourhood poverty level should be used instead of socio-economic 
status as potentially better measure (86, 87). Alcohol and drug use as markers of risk-taking 
behaviour were also reported to be associated with chlamydia (83, 85, 88-90). Countries, where 
it is possible to study ethnicity or migration status, also found an increased risk to contract 
chlamydia (87, 91-94). In return, correct and consistent condom use is reported to be associated 
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with reduced a risk for chlamydia (95). Several studies also investigated association between 
use of oral contraceptive pills among women and risk for chlamydia, but provided inconclusive 
evidence so far (96). Recent studies also looked at the emerged potential contributors of 
increased risk for chlamydia, such as digital dating apps, however no association was reported 
(97).  
 
2.1.1.8 Risk factors for repeated infection 
Repeated chlamydial infections are also common and are results of a failure of the 
antibiotic treatment or from reinfection due to unprotected sexual contact with either an 
untreated existing sexual partner or a new infected sexual partner (98-101). The aim of actively 
promoted testing (screening) is to detect and treat infections, reduce further transmission and 
prevent the sequalae of untreated chlamydia infections (102). The rate of re-infection is found 
to be 29.9 episodes/100 person-years in UK (101), 23.6 episodes/100 person-years in Denver, 
USA (100), and 34 episodes/100 person-years in Indianapolis, USA (98). The rate of 
reinfection is known to be health care facility-, age- and sex- dependant with highest rate among 
those under 20 years of age and among females (100). The risk of reinfection with chlamydia 
decreases with increasing age (e.g., infections is twice as high among those females < 16 years 
compared to with women aged 20-21 years) (103).  
In a recent review the median proportion of females re-infected with chlamydia was 
13.9% (range: 0%–32%) and among males the median reinfection rate was 11.3% (range: 
9.8%–18.3%) (102, 104). Among females, younger age is reported consistently statistically 
associated with a higher risk of reinfection (102, 103), some studies report a relationship 
between race and ethnicity as well (102). In some studies in females, it is demonstrated that a 
co-infection with gonorrhoea increased the reinfection with chlamydia (102). Among males, a 
history of STIs was consistently predictive of reinfection with chlamydia, as well as younger 
age and non-white race (104). High-risk sexual behaviour (incl. not using condoms), change in 
partners and higher number of sexual partners consistently are associated with increased risk 
of reinfection with chlamydia among males and females (102, 104), which also could be linked 
to “core transmitters” (105). Core groups are defined as a smaller proportion of the individuals 
who acquire STIs frequently and transmit them, and thus sustaining the transmission of STIs 
(105, 106). Therefore, it is important that the identification and awareness of high-risk 
individuals is continuously updated. In Sweden, at the time of the beginning of this thesis 
project, no data was available on re-infection. As a result, a prospective cohort study was 
initiated in 2007 in an STI drop-in clinic in Stockholm (107), which Studies I and II are based 
on. 
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2.1.2 Prevalence 
It is possible to identify risk groups for chlamydia via monitoring the positivity rate 
defined as the proportion of positive for chlamydia among individuals tested for chlamydia. 
This measure is used often as a substitute for prevalence (proportion of positive for chlamydia 
in the population in a given time), since prevalence estimates might not be available due to cost 
demanding studies. Positivity rates are regularly evaluated in countries with screening 
programmes (108-111). For instance, in the UK`s screening programme, the positivity rate is 
found to be at its peak at the age of 18 for women with gradual decline, and peak at 19 years 
of age for men, remaining stable up to 24 years of age, and it was found to mirror well the 
reported prevalence (111). Similarly, the positivity rate was reported to approximate well the 
prevalence in other countries (112, 113). However, the increasing proportion of repeated testing 
and repeated chlamydia infections can affect the positivity rate, and as a result overestimate the 
actual prevalence (114). 
In Sweden, we lack population-based chlamydia prevalence estimates. As a possible 
approximation for the prevalence, we use positivity rate among the tested general population. 
Overall, the positivity rate among men is higher than in women through all years even though 
many fewer men are tested for chlamydia: only 30% of all tested individuals are men (Figure 
5). Positivity rate was at its highest in 2007: 8.9% in women and 14.2% in men, which is related 
to the catch-up of nvCT discovered in Sweden in 2006. Since 2010, the positivity rate is 
declining continuously in both sexes, while the number of persons tested is increasing (Figure 
5). 
 
Figure 5. Number of persons tested/tests for chlamydia and positivity rate (%) by sex in 
Sweden, 2000-2018 (source: Public Health Agency of Sweden). 
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Another approach to monitor the effect of control measures is to estimate/measure the 
actual prevalence of chlamydia in the general population. Several European countries were able 
to measure population-based prevalence in the most affected population of 15-29 years of age 
(79, 84, 115, 116). Recent global prevalence estimates (2016) reported a chlamydia prevalence 
of 3.8% (95% uncertainty interval, UI: 3.3–4.5) in women and 2.7% (95% UI: 1.9–3.7) in men 
(37), which was also similar to another recent meta-analysis study (117). Both studies found 
higher chlamydia prevalence in the region of the Americas, the African region, followed by the 
Western Pacific region and the Eastern Mediterranean region (37, 117). In the countries of the 
European Union alone, the chlamydia prevalence (pooled average) in individuals under 26 year 
old was estimated as follows: 3.5% (95% CI 1.9 - 5.2%) among men and 3.6% (95% CI 2.4 - 
4.8%) among women, with a limitation of participation bias due to low response rate in 
included studies (118).  
Efforts to measure the prevalence in biological samples were done over the years in 
selected populations in Sweden as well, such as among visitors of STI clinics and individuals 
ordering chlamydia tests online (78, 119, 120); hence, those studies are prone to selection and 
participation bias (118). Other possible sources of the information on chlamydia prevalence 
could be used from the national behavioural surveys, which collect data on sexual risk 
behaviour and self-reported chlamydia prevalence (121-123). For instance, in the latest 
knowledge, attitude and behaviour survey UngKAB-2015, self-reported lifetime chlamydia 
infection among 20-24 year old women was 14.7% (95%CI: 12.7 – 16.8) and among men 6.8% 
(95%CI: 5.0 – 8.6); among 25-29 year old women was 21.1% (95%CI: 18.6 – 23.5) and among 
men 11.0% (95%CI: 8.8 – 13.2) (122). However, several methodological limitations were 
reported in such surveys (124, 125). Besides, self-reported chlamydia could be biased also due 
to the recall bias. Therefore, we initiated a study to estimate the population-based chlamydia 
prevalence (Study IV). 
 
2.1.3 Sequelae 
In women, untreated chlamydia infections can ascend the upper genital tract and affect 
the reproductive tract causing sequelae, such as pelvic inflammatory disease (PID), ectopic 
pregnancy (EP) and tubal factor infertility (TFI) (72, 126-128). From the summary of the 
studies performed in the 1990-s, it was estimated that 30% of acute PID can be linked to an 
chlamydia infection, but other possible pathogens (Neisseria gonorrhoeae, Mycoplasma 
genitalium) have a potential to cause PID as well (129). In the POPI (prevention of pelvic 
infection) trial in England it was found that 1.6% of women positive for chlamydia at the 
baseline of the intervention arm (screened and treated) developed PID, as compared to 9.5% 
positive for chlamydia in controls at baseline (deferred screening) during the 12 months follow-
up, resulting in RR=0.17 (95%CI: 0.03–1.01) (130). A more recent study in the United 
Kingdom estimated that 20% (95%CrI: 6%–38%) of PID, 5% (95% CrI: 1%–12%) of EP and 
29% (95%CrI: 9%–56%) of TFI are attributed to a Chlamydia trachomatis infection in women 
aged 16–44 years (131). Record linkage studies in Australia reported that during a follow-up 
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after approximately 10 years, women with chlamydia infection had a RR=1.8 (95%CI: 1.6–
1.9) of PID and a RR=1.4 (95%CI: 1.2–1.7) of EP compared to women who tested negative 
for chlamydia (127, 132). Recent estimates suggest that approximately 15% (95%CrI: 5%–
25%) of an untreated chlamydia infection progresses to a clinical PID (72), while earlier 
estimates showed that up to 40% of untreated chlamydial or gonococcal infection in women 
can develop into PID (133). On the other hand, a study based on the data from the Netherlands 
estimated that 0.43% progress to a clinical PID, 0.07% cause ectopic pregnancy, and 0.02% 
causes tubal factor infertility in women with a current chlamydia infection (134). Thus, authors 
concluded that earlier assumptions regarding sequelae were overestimated, thus, cost-
effectiveness of the screening programmes could be considered not favourable (134).  
A recent review also reported a significant relationship between chlamydia and EP 
(OR=3.03; 95%CI: 2.37–3.89) (126). Another review also found a relationship between 
chlamydia infection and pregnancy harms, such as increased risk for spontaneous abortion 
(RR=1.5; 95%CI: 1.2–1.9) and stillbirth (RR=1.3; 95%CI: 1.1–1.5), and this consequence was 
more pronounced in low- and middle-income countries in comparison with high-income 
countries (135). However, since these estimates are produced based on studies that used various 
kinds of methodologies (randomized trials, observational studies) and populations, there are 
challenges in ascertaining the sequelae since the timing of the PID and other long-term sequelae 
are still debatable and the imprecision of the estimates and biases should therefore be 
considered (2, 136).  
Studies also reported that an increasing number of repeated chlamydia infections are 
associated with increased odds for PID (137, 138). For instance, two chlamydia infections had 
OR=4.0 (95%CI: 1.6–9.9), while three or more chlamydia infections had OR=6.4 (95%CI: 2.2–
18.4) for PID (137). 
Although much attention had been paid to the sequelae in women, there are also 
suggested sequelae in men due to chlamydia infection, such as chronic prostatitis/chronic 
pelvic pain syndrome and epididymitis, which can affect spermatogenesis and fertility (139-
141). Nevertheless, the role of chlamydia in male infertility is still debatable (142). 
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3 CHLAMYDIA CONTROL AND PREVENTION IN SWEDEN 
3.1.1 Surveillance system 
Chlamydia infection is a mandatory notifiable disease in Sweden since 1988 according 
to the Communicable Disease Act (143). However, testing for chlamydia has been available 
since the early 1980s, with reporting from the laboratories starting already in 1982. Currently, 
a commonly agreed case definition within the EU is used for reporting chlamydia to the 
international and national level (144). The chlamydia surveillance system is case-based, 
passive and universal. The electronic surveillance system SmiNet-2 is operating since 2004, 
with all laboratories and health-care clinics having access to report cases (145). Each laboratory 
report verified chlamydia case from any anatomical site to the system electronically, as well as 
do clinicians (Figure 6). All residents in Sweden have an unique personal identification 
number (PIN), which is used for the reporting to SmiNet-2 (146). However, notifications of 
STIs and HIV do not contain full identity; instead, a shortened identification number (Swedish, 
rikskod) is used for reporting. This number is not unique any longer, which prevents the 
automatic linkage of the laboratory notification with the clinical notification. Therefore, only 
the clinical chlamydia notifications are used for the official statistics. The system is accessible 
to County Medical Offices (their county-specific data only) and the Public Health Agency of 
Sweden, which has access to all data on a national level. The system was evaluated for the 
period 1997-2008, and was found to provide accurate and relevant data for action (147).  
 
 
Figure 6. Schematic presentation of electronic surveillance system in Sweden. 
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3.1.2 Opportunistic testing  
As part of the secondary prevention (Figure 7), testing for chlamydia (as for gonorrhoea, 
syphilis and HIV) in Sweden is available free of charge for everyone who wishes at all health-
care facilities and it is covered by the County Council budget. Current (2015) national 
guidelines recommend chlamydia testing for anyone who had new or unprotected sexual 
contacts during the past year (148). Individuals should be offered testing for chlamydia in any 
health care facility as part of the opportunistic testing (opportunistic screening) strategy in 
Sweden. Asymptomatic persons could test themselves as early as 7–10 days after an 
unprotected sexual contact. However, regional guidelines for chlamydia testing can be more 
explicit; for instance, in the Skåne Region, individuals, who previously had a chlamydia 
infection and/or gonorrhoea, are considered at higher risk, and are recommended to be offered 
testing for chlamydia (149). Another example is the Västerbotten Region, where re-testing for 
chlamydia 2 months after the initial chlamydia infection is explicitly recommended (150). 
Specialized clinics are performing most of the chlamydia testing: STI clinics and youth health 
clinics (65% of all notified cases in 2019), gynaecology, maternal care and family planning 
clinics (12% of the cases) (151). General practices could be a valuable asset for the STI testing, 
although they reported only 13% of the total cases in 2019. Efforts were made to increase 
engagement of general practices in chlamydia testing in Sweden (152). During 1992-2018, 
almost 12 million tests were performed in Sweden (32). Of those tests, 77% were performed in 
women during the period of 1992-2004 as in contrast to 68% during the period of 2009-2018 
(153). On average, 66% of all tests were reported in the age group 15-29 years (data available 
for 2009-2018) (153). 
 
 
Figure 7. Interventions for chlamydia control (image source from reference (154), 
reproduced with permission). 
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In the beginning of 2000s, online services started to develop in Sweden (contracted by 
the County Councils) offering self-samples for chlamydia at individual´s homes (155). The 
operation of such testing is feasible due to a unique PIN. The sampling kit is sent home for self-
sampling, and is then returned to the laboratory for the testing. The results of the tests are 
obtained online by using the PIN. In case of a positive result, patient are referred for clinical 
management and partner notification. Simultaneously, positive findings are reported 
electronically to the surveillance system SmiNet-2. Currently, all counties (n=21) in Sweden 
offer such online services through various providers as for example the 1177 Vårdguiden 
(national health guidance service). The data on number of tests ordered exclusively online are 
not routinely collected at the national level. Nevertheless, a recent study evaluated online-based 
testing, performed in 14 counties, found that the proportion of such tests increased from 11% 
in 2013 to 18% in 2017 (156). This study also found that internet-based testing had a more 
substantial increase among women (by 115%) than among men (by 71%) during the study 
period of 2013–2017.  
Opportunistic testing as part of the control strategy (Figure 7) was never formally 
evaluated in Sweden. Several studies reported limited evidence of effectiveness and cost-
effectiveness of opportunistic screening on averted sequelae and chlamydia prevalence (157-
159). A systematic screening programme was piloted for 3 years in the Netherlands, and was 
discontinued due to lack of effectiveness (160). Currently, only England (UK) has a systematic 
screening programme in place (161).  
 
3.1.3 Laboratory diagnostic methods 
Laboratory methods for the identification of Chlamydia trachomatis have developed 
over the years and comprise both direct and indirect methods. The direct methods include cell 
culture, which was considered to be a golden standard (162). However, the culture method is 
dependent on the correct specimen collection, storage and transportation. The sensitivity of the 
culture method is less than 75%, however, the specificity is high (up to 100%) (163). Other 
various non-amplification methods, which were based on antigen detection and nucleic acid 
hybridization methods are no longer considered up to date. These methods had a sensitivity 
between 50%–75% (164), and no longer considered recommended methods for chlamydia 
diagnostics. Nucleic acid amplification tests (NAATs) came to use in Sweden in the late 1990s, 
and are based on the amplification of nucleic acid sequences of the pathogen. Due to the high 
sensitivity, specificity, and considerable speed of diagnosis, NAATs became a method of 
choice and is currently considered a golden standard method (165). Various commercial 
NAATs are available in the market, and their performance is depending on the sample type 
used for diagnostic. In women, sensitivity of NAATs was estimated above 93%-95% for first-
void urine specimens, above 97% for clinician– and self-collected vaginal swabs, above 91%-
93% for endocervical swabs (166, 167). The specificity was estimated above 99% for all female 
urogenital specimen types (166, 167). In men, sensitivity for first-void urine specimens was 
estimated 99%-100%, while specificity above 98% (166, 167). In women, due to the relatively 
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lower sensitivity for urine specimens, vaginal swabs are the preferred specimen, which have 
similar sensitivity and specificity to cervical swabs (165, 168). For pharyngeal, rectal and 
conjunctival specimens, NAATs can be used, but their lower sensitivity and specificity should 
be considered for these type of specimens (165). Recently two NAATs were approved by the 
Food and Drug administration Agency in the USA for diagnostic testing of extragenital 
specimens (169). 
Indirect diagnostic methods, such as serological testing, is not used for the diagnosis of 
chlamydia as the method cannot discriminate between current and past infection. However, 
serology continue to be used in epidemiological research to study chlamydia prevalence and 
possible correlation with infertility in women (170-173).  
In addition to the laboratory-based tests, rapid tests at the point of care (POC tests) 
become more attractive for the users as results are available in a short time (approx. 30 min) 
(163). The advantage of these tests is also, that patients can receive counselling and treatment 
without any delay (163). However, in a recent systematic review, the authors reported the 
sensitivity of POC tests to be 48% and specificity 98%, which hinders to recommend these 
assessed tests for the triage of urogenital chlamydia (163).  
 
3.1.4 Treatment 
In Sweden, uncomplicated chlamydia can be treated at health care facility where it was 
diagnosed, while complicated chlamydia cases are referred to specialized STI clinics. 
Treatment guidelines in Sweden (148) are in line with European guidelines (165), with 
recommended first-line treatment is Doxycycline for urogenital uncomplicated chlamydia. 
Alternatively, treatment with Azithromycin could be prescribed if the first-line treatment is not 
possible, and the diagnosis with Mycoplasma genitalium is ruled out (148). This is due to the 
resistance development by M.genitalium against Azithromycin (174). True antimicrobial 
resistance of C.trachomatis is rare; however, treatment failures have been reported, most likely 
due to poor compliance, tolerance to treatment, or reinfection (175, 176). Test of cure is not 
routinely recommended for uncomplicated chlamydia cases, but could be done if there is a 
suspicion of non-compliance to the treatment or the first-line treatment is not used. Expedited 
partner therapy (patient delivered partner therapy) is not a praxis in Sweden, since treatment 
has to be pathogen-based and requires laboratory testing before treatment initiation (148). In 
some countries, expedited partner therapy is permitted and could be beneficial to reach 
partners, and reduce the transmission of chlamydia (33, 165).  
 
3.1.5 Partner notification 
Partner notification (PN, partner referral, contact tracing) is a process of identifying 
contacts of index chlamydia cases and is part of a control programme in Sweden, legally 
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regulated by the Communicable Diseases Act (143). Partner notification has important effects 
both on an individual level (by preventing re-infection of index case) and at the population 
level (by reducing the transmission of the chlamydia infection) (177). Several modelling 
studies suggest that PN (together with screening) strategies are effective tools in averting 
chlamydia cases and reducing chlamydia prevalence and could be cost-effective with some 
scenarios (178, 179). 
International guidelines recommend either provider referral or patient referral to reach 
contacts 2 to 6 months back in time (33, 180). In Sweden, the Communicable Diseases Act 
indicates that contact tracing (Swedish, smittspårning) has to be performed by specially trained 
staff, for instance, social workers and midwifes (143). The same law defines the obligation of 
the index case and his or her contacts to participate in the partner notification process. The 
evidence suggests (181) that partner notification should be carried out to up to 12 months back 
in time, which is also recommended for the health care providers (182). Local county-specific 
guidelines recommend partner notification 6 to up to 12 months back in time. In Sweden, 
several counties have a centralized contact tracing service, where index chlamydia cases can 
be referred for partner notification (183). This approach showed better results in reaching 
partners as compared to the single individual health care providers (not specialized in partner 
notification) (181, 184). Quality indicators were suggested on the partner notification process 
(e.g. how soon the partner notification started and finished, how far back in time it was 
performed etc.), and are important to follow up on by health care clinics and County Medical 
offices (182).  
 
3.1.6 Primary prevention  
Controls on chlamydia infection through the primary prevention (Figure 7) activities 
include sexuality education in the school curriculum, which is compulsory in Sweden since 
1955 (185). Sexual health promotion is a key component, where several actors, in addition 
to the schools, are involved. One of the non-governmental organizations that has been 
particularly involved is the Swedish Association for Sexuality Education (Riksförbundet för 
Sexuell Upplysning - RFSU) (186), who started prevention work as early as 1933. The 
network of youth health clinics across the country is in addition to providing medical care, 
also offering counselling on safe sex, mental health, and prevention of alcohol and drug use 
for individuals aged 13-25 years. They are also possible to interact with through their 
websites (187) and through social media. Youth health clinics were introduced in the 1970s 
and have grown in number, reaching 250 facilities in 2018 (188). All these actors are 
important collaborators to fulfil objectives of the National Action plan for chlamydia 
prevention launched in 2009 (189). The main themes to pursue by the plan were to increase 
condom use with casual partners, the understanding of consequence of unsafe sex and to 
increase the number of persons tested for chlamydia. Additionally, through the years, 
information campaigns promoting condom use and testing were run by governmental and 
non-governmental organizations at the national and regional level. One such initiative has 
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been in place since the early 2000s, called Chlamydia Monday, promoting testing for 
chlamydia. The campaign was shown to be a cost-effective initiative (2007) (190). 
As part of the primary prevention, vaccines could be an effective tool in controlling 
STIs. Because of the highly effective vaccines for human papillomavirus infection, a 
remarkable decrease in HPV infections (191) has been seen, with the potential to eliminate 
cervical cancer (192). Modelling studies have suggested that a potentially effective 
chlamydia vaccine could control and even eliminate chlamydia infections (193-195). 
Intensive research is currently going on, with the hope of finding a chlamydia vaccine in the 
near future (196).  
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4 RESEARCH AIMS 
 
The aim of this thesis work is to gain enhanced understanding on chlamydia epidemiology in 
Sweden.  
The specific aims of the studies are as follows: 
Study I: To investigate how sexual behaviour, testing behaviour and demographic factors are 
associated with chlamydia infection diagnosis. 
 
Study II: To identify unobserved groups (latent classes) based on sexual behaviour and 
substance use patterns; and study how latent class membership is associated with repeated 
chlamydia testing and repeated chlamydia infection. 
 
Study III: To examine and compare chlamydia infection notification trends before and after 
emergence of the new variant of Chlamydia trachomatis (nvCT) in Sweden. Additionally, to 
study the association between testing for chlamydia and chlamydia notification rates prior and 
after emergence of the nvCT. 
 
Study IV: To estimate population-based Chlamydia trachomatis prevalence in Sweden.  
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5 MATERIALS AND METHODS 
5.1 OVERVIEW 
The overview of the aims and study designs are presented in Table 2. 
Table 2. Overview of study designs included in the thesis. 
 Study I Study II Study III Study IV 
Study outcome 
 
Association of 
demographics, 
sexual and testing 
behaviour with 
chlamydia 
diagnosis. 
 
Latent classes 
based on sexual 
behaviour and 
substance use 
patterns.  
 
Association of 
latent classes 
with repeated 
testing and 
chlamydia 
infection. 
Trend and cyclic 
component 
before and after 
emergence of the 
nvCT in Sweden.  
Association 
between testing 
and chlamydia 
rates before and 
after emergence 
of the nvCT. 
Chlamydia 
prevalence and 
incidence rates  
Study design Cohort (cross-sectional) Population-based 
longitudinal 
Population-
based 
mathematical 
modelling 
Study population Men and women aged 20–40 years 
attending an urban STI-clinic 
Total Swedish 
population  
Men and 
women aged 
15-29 years 
living in 
Sweden 
Statistical  and 
mathematical 
analysis 
Log- binomial and 
Poisson regression 
Latent class 
analysis, 
ordinal and 
multinomial 
logistic 
regression  
Time series 
analysis with 
negative 
binomial 
regression 
Compartmental 
deterministic 
mathematical 
model  
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5.2 DATA SOURCES 
5.2.1 Cohort study (Study I and II) 
A prospective cohort of visitors to a drop-in STI clinic in Stockholm was recruited 
between December 2007 and June 2008 (107). The clinic served the population aged 20 years 
and older. Annually approximately 15 000 visits were made, of those 60% by men (107). 
Inclusion criteria in the study were as follows: 20–40 years of age, accepting to answer a paper 
questionnaire before testing for chlamydia, and accepting to link with the subsequent 
Chlamydia trachomatis laboratory testing result. All visitors presenting for chlamydia testing, 
irrespective of symptom presence, were consecutively invited to take part in the study.  
5.2.1.1 Exposures 
The questionnaire consisted of several parts, including the following themes: 1) 
demographic background (gender, age); 2) testing for and having had STIs; 3) sexual 
experiences/behaviour (e.g. number of sexual partners during the past 12 months, current 
steady relationship, condom use with new or casual partners); 4) substance use (alcohol and 
drug use during the past 6 months); and 5) gender-specific exposures: for men – getting a 
woman unintentionally pregnant, and for women – having used emergency contraceptive pills 
(107). Information on presenting symptoms was extracted from a case report form by health-
care staff at the clinic. All abovementioned variables were considered as exposures in Study I. 
For Study II, fewer number (n=9) of variables were included into latent class membership 
analysis, such as reason for the testing, current steady relationship and concurrent sexual 
partnerships, number of sexual partners during the previous 12 months, type of last sexual 
partner, condom use and responsibility with new/casual partners, alcohol and drug use during 
the previous 6 months, and self-assessed alcohol impact. 
 
5.2.1.2 Outcomes 
The outcome of Study I was Chlamydia trachomatis diagnosis (positive or negative) 
verified by DNA amplification assay (ProbeTec™ by Becton-Dickinson, USA) from the 
samples provided by study participants; from women, self-collected vaginal swab put into first 
void urine, and from men, urine samples. All chlamydia-positive individuals received treatment 
free of charge according to the established treatment protocol. Chlamydia patients also 
underwent a mandatory partner notification process.  
We had two outcomes in Study – II: repeated testing and being infected repeatedly with 
chlamydia. For each outcome, we looked at short-term and long-term measures. For the short-
term testing outcome we used repeated testing for chlamydia during the past 12 months 
(no/yes) and for the long-term testing we used repeated lifetime testing for chlamydia (no, 1-3 
times, 4 or more times). Accordingly, for chlamydia infection short-term outcome we looked 
at current chlamydia test result (negative/positive) at the time of the study and for long-term 
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outcome: lifetime chlamydia infection (never, once, twice or more). No and never were 
considered as reference levels in all outcome analyses. 
 
5.2.2 Infectious diseases register SmiNet-2 (Study III and IV) 
5.2.2.1 Data on incident Chlamydia trachomatis cases 
We retrieved cases of Chlamydia trachomatis infection from the national population-
based register on mandatory reportable infectious diseases (SmiNet-2) at the Public Health 
Agency of Sweden (PHAS) (145). All laboratory confirmed cases of chlamydia from any site 
of the body (urogenital, pharyngeal and anal samples) are mandatory notifiable in Sweden 
(143). Ninety-five to ninety-seven percent of reported chlamydia cases were acquired via 
sexual contact, with most of the remaining cases having no information on the route of 
transmission, and very few cases acquired via vertical transmission (0.05–0.1%).  
For Study III, we aggregated chlamydia cases by 4-week months (here called a “month”), 
resulting in 13 months of equal length per year (also called the Equal Month calendar), except 
for extra days in week 53 in some years, which were added to the last week of month-13. From 
the information available on the cases, we were able to aggregate cases by county group, based 
on their ability to detect nvCT in 2006 (52, 197): able-to-detect (n=8) and unable-to-detect 
(n=13). For the yearly analysis, we aggregated chlamydia cases by year to relate to the annual 
data to number of persons tested. We used mid-year population counts that were obtained from 
Statistics Sweden by year and county (198). We carried out analyses for two periods: 1992–
2004 (before nvCT) and 2009–2018 (after nvCT). We excluded data for the period 2005–2008: 
2005–2006 due to potentially missed cases of nvCT; 2007–2008 data were excluded due to a 
spurious incidence peak and subsequent decrease caused by catch-up of nvCT. 
For Study IV, we retrieved reported chlamydia cases and number of cases by reason for 
testing (partner notification, screening or symptoms), and type of infection (symptomatic or 
asymptomatic) from the national register of mandatory notifiable diseases SmiNet-2 (147) at 
PHAS. We aggregated data by age group (15–19, 20–24, 25–29 years of age), sex and year 
(2009, 2012, 2015 and 2018). For symptomatic cases, we extracted data on the number of days 
from the onset of the disease to verified diagnosis of chlamydia at the reporting health-care 
facility. Reported chlamydia cases with missing information on symptomatic or asymptomatic 
infection were assigned proportionally between both categories assuming that their distribution 
was the same as the cases with observed information. The same procedure was done for reason 
for the testing, where PN is one of the reasons for testing.  
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5.2.2.2 Data on testing for Chlamydia trachomatis 
For Study III, we used population-based reported annual number of persons tested for 
chlamydia collected at the PHAS. The number of persons tested are reported from the 
microbiological laboratories in charge of chlamydia testing in each county, which serve all 
health care facilities (private and public). For the period 2009–2018, on average 23.4% of 
counties reported the number of tests performed instead, which could include multiple tests 
done on the same person at the same testing event (data not available for the first period). As 
the reported testing data was in aggregated format, it was not possible to eliminate potential re-
counts, and we chose to interpret and refer to both types of data as number of persons tested in 
our analyses. We defined the proportion of persons tested as the number of persons tested 
(including tests performed) per population aged 15–64 years in each county, being the age 
interval where most tests are performed. Proportions of tests per population were aggregated 
nationally and by county group. We used mid-year population counts of ages 15–64 years from 
Statistics Sweden by year and county (198).  
For Study IV, we retrieved number of annual persons tested aggregated by age groups 
15–19, 20–24, 25–29 years of age and by sex, collected at PHAS. Data was retrieved for the 
following years: 2009, 2012, 2015 and 2018. 
 
5.2.3 Other data sources (mathematical modelling, Study IV) 
From a cohort study among visitors to a STI clinic, we used data on the reason for testing 
on chlamydia negative persons (120). Thus, we calculated the PN rate for uninfected 
individuals by sex and for two age groups (20–24 and 25–29) in 2009. We assumed the same 
PN rate for uninfected as a known quantity for 2012, 2015 and 2018, and for 15–19 years old.  
The size of the sexually active population by sex and age group was obtained from the 
2015 population-based knowledge, attitude, behaviour survey UngKAB2015 among 
individuals 16-29 years old (122), using the question on whether the participants ever had sex. 
We applied the same estimate to all years in our analysis.  
Parameters on chlamydia natural history and sensitivity/specificity of the laboratory test 
were obtained from published literature, as described in Table 2 in the Paper IV. All rates are 
in units per year. 
The population size by age groups and sex was obtained from Statistics Sweden (198). 
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5.3 STATISTICAL METHODS (STUDIES I-III) 
5.3.1 Log-binomial regression and Poisson regression (Study I) 
For the dichotomous outcome data logistic regression models are often applied, with 
estimation of odds ratios (ORs). However, for the frequent outcomes, which are common in 
cross-sectional studies, the OR can strongly overestimate the relationship. Therefore, for the 
cohort data other alternative regression models could be applied to estimate risk ratios (RRs), 
such as log-binomial regression and Poisson regression (199). Both models are generalized 
linear models and use a log link function to relate predictor variables with the outcome (200). 
Log-binomial model assumes that dependent variable has Binomial distribution. The maximum 
likelihood approach is used to obtain estimates and they are reported to have small variances, 
and are unbiased and efficient (201). However, log-binomial regression models experience a 
high number of failures, such as non-convergence (202). In Study I, we were able to estimate 
crude RR associated with chlamydia diagnosis using log-binomial regression. For the 
multivariable analysis, a log-binomial model with the outcome chlamydia diagnosis had 
convergence problems, so instead we fitted a multivariable Poisson regression model with 
robust standard errors estimated through a sandwich estimator (203). The Poisson regression 
is typically used when the outcome is count data of diagnoses (events) occurring over time, but 
can be applied to the dichotomous counts (disease/ no disease) as well (204). The Poisson 
regression model assumes Poisson distribution where the mean is equal to the variance, where 
the variance increases when the mean increases. Because counts/events are positive numbers, 
the distribution is highly positively skewed and therefore overdispersion is present (i.e., the 
variance is greater than the mean) (205).  
Due to missing values in our dataset, we created 100 imputed datasets for model building, 
where plausible values for missing responses were imputed. The implementation of the 
imputation algorithm for our dataset is described elsewhere (206).  
 
5.3.2 Latent class analysis (Study II) 
Latent class analysis (LCA) is a statistical method belonging to finite mixture models. 
LCA aims to find underlying hidden (latent) groups in the observed population through the set 
of observed variables (manifest variables). The method is based on estimation of conditional 
response probabilities and the latent classes (LCs) prevalence using maximum likelihood 
criterion based on a set of chosen categorical variables (207). Identified patterns amongst a set 
of given variables produce LCs, where each respondent is assigned to the LC with the highest 
estimated probability. These LCs are mutually exclusive. The main assumption in the LCA is 
that observed variables are not highly correlated within the identified LC, known as local 
independence (208, 209). This analysis approach allows to capture how multiple variables co-
occur and interact with each other (a model-based clustering method), as opposite to the 
conventional regression analysis (variable-oriented analysis), where the association between 
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independent variable and outcome variable is examined while holding other variables constant. 
We fitted models with varying numbers (2 to 5) of LCs based on the observed 9 manifest 
variables (Figure 8A). The analysis was stratified by sex. We labelled latent classes based on 
the item-response probabilities of the respondents. 
 
 
Figure 8. Schematic depiction of analysis steps in latent class analysis study. 
 
5.3.3 Ordinal logistic regression and multinomial logistic regression (Study 
II) 
The distal outcomes in study II were dichotomous (for variables: repeated testing for 
chlamydia during previous 12 months, current chlamydia test result) and ordinal categorical 
with three response categories (for variables: repeated lifetime testing for chlamydia, repeated 
lifetime chlamydia infection) (Figure 8B). The relationship between LCs and these outcomes 
was assessed by applying an ordinal logistic regression model (210). The main assumption in 
this model is that the odds and the odds ratios are the same across categories of the outcome, 
hence proportional odds assumption. The null hypothesis of proportional odds can be assessed 
statistically via the Brant test (211). In case this assumption is violated, as it happened with one 
of our outcomes (Lifetime chlamydia infection in men), the multinomial (polytomous) logistic 
regression model can be used instead (212). The latter model allows varying relationship 
between exposure and categories of the outcome. Both models yielded ORs. 
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5.3.4 Time series negative binomial regression (Study III) 
Time series are sequences of data points (disease, events) ordered in time, usually equally 
spaced in time. The main feature of time series is that observations close in time tend to be 
correlated with each other, which should be accounted for in the analysis (213). In study III, 
we investigated time series of reported incident chlamydia cases with monthly interval, and 
yearly interval when adjusted for the testing. Several models are applied to study time series, 
decomposition method and autoregressive integrated moving average (ARIMA) models are 
among the most popular ones in biomedical research (214). We chose a decomposition method, 
which extracts the underlying pattern from the time series: trend and seasonality. The trend 
characterises the long-term changes, and seasonality characterises cyclic changes within time: 
seasons of the year, holiday breaks etc.  
Within the decomposition approach, we fit negative binomial regression models for 
chlamydia notification counts with corresponding population counts as the denominator. As 
described above, due to overdispersion of count data (incident chlamydia cases), the negative 
binomial regression model was a better choice than Poisson model (215). Negative binomial 
regression is based on the assumption of a Poisson-like distribution and handles overdispersion. 
Our models included an overall non-linear trend, overlaid with monthly effects to capture 
seasonal variations in incidence, and were adjusted for autocorrelation, i.e. correlation between 
numbers of cases from month to month. We modelled trends as restricted cubic splines (216) 
to capture non-linear features of the data in 1992–2004 and as a linear trend during period 
2009–2018. Initially, seasonality was modelled with sine and cosine function, but due to 
asymmetrical behaviour of the cyclic component in our data we had to use another solution. 
Therefore, seasonality was modelled as fixed monthly effects averaging to zero over a full year. 
The models were fitted via maximum likelihood. We expressed the trend as monthly incidence 
rates (IRs, notified cases per 100 000 population) and seasonality as incidence rate ratios 
(IRRs), calculated as the ratio of each monthly IR relative to the average annual chlamydia IR 
for the corresponding year. Similarly, we fitted negative binomial regression models for the 
annual chlamydia IRs with population as an offset and adjusted for individual counties as fixed 
effects. Due to yearly aggregation of the data, we were unable to study seasonality in this 
model. Therefore, we estimated only annual trends of chlamydia IRs adjusted for the testing.  
 
5.4 MATHEMATICAL MODELLING (STUDY IV) 
The aim of the mathematical models is to describe transmission dynamic of the disease, 
where demographic, behavioural and biological factors play a role (217). The models are used 
for either prediction or understanding, and usually are simplifications of the complexity of the 
interrelation between pathogen and host. In the field of modelling infectious disease, various 
transmission models have been developed using classification of populations into susceptible 
(S), infected (I) and recovered (R) (218), a SIR model. These population subgroups (S, I, R) 
are referred in the model as compartments, which also gave a name to the compartmental 
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model. However, due to short-term complete immunity for chlamydia infection (219), 
recovered (R) are often disregarded from the model, resulting in a SIS (Susceptible-Infected-
Susceptible) model. Individuals move between compartments with a certain rate, which is 
described by mathematical equations, which allows to estimate unknown parameters.  
In study IV, we extended a deterministic compartmental SIS transmission model without 
demographic processes (birth and death) (114). The model is based on the surveillance data 
(chlamydia cases and testing), health care-seeking behaviour and chlamydia infection natural 
history. The main attribute of the deterministic model is that the model will generate the same 
outcome as compared to the stochastic model. In the model, uninfected (U) individuals become 
either symptomatic (S) or asymptomatic (A) at a certain rate (Figure 9). Symptomatic 
individuals seek health care where they are diagnosed and treated (at a rate of diagnosis), and 
then return to uninfected status. Asymptomatic infections are detected through screening 
programmes (at a rate of screening) or due to spontaneous clearance of chlamydia infection 
and return back to uninfected. Both S and A can also be identified by partner notification (PN), 
a parameter that we introduced in the model and allowed different rates depending on symptom 
status. The model assumes that the asymptomatic are tested with the same probability 
regardless of the risk behaviour. We calculated the testing coverage rate, the symptomatic 
diagnosis rate, and the asymptomatic diagnosis rate for sexually active population by sex and 
age groups. The model also takes into consideration the probability of true positive and false 
positive laboratory test results. Using the compartment model, we can describe the disease 
dynamics with a set of differential equations (Online Supplement Part 1 of Paper IV) and solve 
unknown parameters (Table 1 in Paper IV). We assumed that the model is in steady state, which 
implies that the number of uninfected, symptomatic and asymptomatic individuals does not 
change with time, i.e. per year.  
 
Figure 9. Schematic depiction of the model (U – uninfected individuals, A – asymptomatic 
chlamydia cases, S – symptomatic chlamydia cases). 
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We sampled each of the parameters 10 000 times from the appropriate assumed 
distributions (Table 2 in Paper IV), and assigned distribution to the reported data to obtain 
outcome estimates with uncertainty, 95% credibility intervals (CrI). We performed sensitivity 
analyses by testing one parameter at a time to evaluate how much each parameter has affected 
the outcomes. We varied the following parameters: the symptomatic testing rate, the 
asymptomatic testing rate, the probability of a false positive test, the probability of a true 
positive test, and the fraction of diagnosed cases that are asymptomatic, while using sampled 
distributions of size 10 000 for the remaining parameters.  
 
5.5 ETHICAL ASPECTS 
In studies I and II, we utilized data from questionnaires and clinical test for chlamydia 
collected at an STI clinic in Stockholm. All study participants were informed about the study 
aims and procedures, and were provided with written informed consent. In order to link the 
questionnaire and a clinical result, a study number was assigned to each study participant. In 
addition to the consent form, a contact form with study participants PIN and address details 
was generated for the follow-up invitation. The key for linkage of PINs and study numbers was 
kept separately in a secure file. All paper questionnaires were kept in locked storage. All 
individuals tested positive for Chlamydia trachomatis received treatment free of charge, and 
underwent partner notification according to the guidelines at the time. In addition, these 
individuals were offered test of cure approximately 4 weeks after being tested positive for 
chlamydia. According to the Biobanks in Medical Care Act (220), all clinical specimens were 
destroyed after the end of the study. For studies I and II, ethical approval was obtained from 
Regional Ethics Review Board in Stockholm (reference number: 2007/933-31/4). A 
supplementary application to Regional Ethics Review Board in Stockholm (reference number: 
2011/313-32) was granted regarding change of research principal investigator. 
In study III, we extracted data on chlamydia cases and number of tests from the national 
register for infectious diseases SmiNet-2, aggregated by county type and year. Aggregation 
level did not allow identifying individuals. However, we still applied for and received ethical 
approval for this study from the Regional Ethics Review Board in Stockholm (reference 
number: 2012/1710-31/3). 
In Study IV, we used secondary data in aggregated format (age groups and sex), which 
did not allow identifying individuals. Additionally, we used parameters for the model from the 
published references. Therefore, ethical review was not required. 
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6 MAIN FINDINGS 
 
6.1 STUDIES I AND II 
6.1.1 Characteristics of the study participants 
During the recruitment period, 2 814 individuals visiting an STI clinic agreed to take part 
in the study (recruitment rate: 53.7% (2 814/5 244)). Out of 2 814 respondents, 1 378 (49%) 
were women and 67.3% were single. The mean age was 27.4 years (27.0 for women and 27.8 
for men). The median number of sexual partners during the previous 12 months was four 
partners for both sexes. The median number of casual sexual partners for women was two, and 
for men was three during the previous 12 months as reported by 74% of respondents. Of the 
study participants, 30% never or seldom used condoms with new or casual partners. During the 
past 6 months, 90% of participants used alcohol and 10% used drugs before having sex. A 
considerable proportion of the study participants reported lifetime testing for chlamydia (82%, 
2 310/2 814), and 60% reported lifetime testing for HIV. 
 
6.1.2 Factors associated with chlamydia infection 
In this cohort of visitors to an STI clinic, 303 (10.7%) tested positive for Chlamydia 
trachomatis, with a higher positivity rate observed among men (12.6%) than in women (8.9%). 
We identified the following independent factors associated with a statistically significant 
increased risk for chlamydia: being 20–24 years old, being tested due to partner notification; 
symptoms as reason for testing; reporting 6–10 sexual partners during the previous 12 months; 
reporting last sexual contact as “petting, vaginal, oral, and anal sex”; consuming alcohol before 
having sex; as well as presenting symptoms (Table 3). We also identified a statistically 
significant strong protective effect of having been tested for chlamydia during the past 12 
months compared with not being tested (Table 3). 
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Table 3. Factors associated with Chlamydia trachomatis diagnosis  
* P-value from Wald test; ** P=0.017 for the interaction term “Gender x Symptoms” 
 
Covariate Adjusted Risk Ratio 
(95% Confidence Interval) 
P-value* 
Gender 
- Women 1.15 (0.84 - 1.56) 0.382 
- Men 1.00   
Age group 
- 20-24 2.10 (1.21 - 3.65) 0.008 
- 25-29 1.57 (0.91 - 2.72) 0.105 
- 30-34 1.47 (0.81 - 2.66) 0.206 
- 35-40 1.00   
Reason for current chlamydia testing 
- Casual sex/ check-up 1.00   
- Contact with chlamydia case/PN 6.55 (4.77 - 8.98) <0.001 
- Symptoms 2.19 (1.48 - 3.24) <0.001 
Ct test (past 12 months) 
- No 1.00   
- Yes 0.72 (0.55 - 0.94) 0.014 
- Don't remember 1.10 (0.65 - 1.87) 0.730 
Number of sexual partners (past 12 months) 
- 0-2 partners 1.00   
- 3-5 partners 1.12 (0.81 - 1.55) 0.498 
- 6-10 partner 1.53 (1.06 - 2.21) 0.023 
- ≥11 partners 1.61 (0.94 - 2.76) 0.082 
Time since the last sexual contact 
- Last 7 days 0.70 (0.48 - 1.01) 0.056 
- 1-4 weeks 0.95 (0.66 - 1.37) 0.784 
- 1-3  months 1.00   
- ≥4 months 1.47 (0.71 - 3.05) 0.301 
- Don´t remember 1.37 (0.20 - 9.43) 0.751 
Type of the last sexual contact 
- Vaginal, oral and petting 1.00   
- Vaginal  1.17 (0.86 - 1.61) 0.319 
- Vaginal and oral  0.77 (0.51 - 1.17) 0.219 
- Vaginal and petting  0.81 (0.47 - 1.40) 0.460 
- Vaginal, oral, petting and anal 1.84 (1.09 - 3.10) 0.023 
Alcohol use before having sex (past 6 months) 
- Yes 1.98 (1.10 - 3.57) 0.023 
- No 1.00   
Men presenting symptoms at clinic visit** 
- Yes 2.09 (1.38 - 3.18) 0.001 
- No 1.00   
Women presenting symptoms at clinic visit** 
- Yes 1.08 (0.71 - 1.65) 0.706 
- No 1.00   
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6.1.3 Latent classes by sex 
In study II, we were able to study a pattern of behaviours in order to identify unobserved 
(hidden) latent classes (LCs) as in contrast to study I where we studied independent factors. 
Based on nine selected observed variables, we identified four LCs for men and three LCs for 
women with increasing gradient of sexual risk behaviour, with class 1 being the least risky 
behaviour. We interpreted, labelled and ordered the latent classes based on the item-response 
probabilities. Among the men, 8% (n= 110) fell into class 1, labelled “Mixed steady and non-
steady partnerships, low substance use” (Figure 10). Thirty percent (n= 441) of the men fell 
into class 2, labelled “Steady partnership with/without concurrent partners”. They were 
considered medium risk, with a low probability of not having a steady current relationship and 
a higher probability of many sexual partners with and without concurrent relationships. For the 
men, we could further separate LCs of high-risk behaviour: “Non-steady partnerships with 
many partners, condom users” (class 3, n = 601) and “Non-steady partnerships with many 
partners, condom non-users” (class 4, n= 284), comprising 42% and 20% of the men, 
respectively. 
Amongst the women, 10% (n=134) fell into class 1 of low-risk sexual behaviour, labelled 
“Mixed steady and non-steady partnerships, low substance use” (Figure 11). Figure 11. 
Latent class conditional probabilities for women (N=1 378)Thirty-two percent (n=441) of 
the women fell into the class 2, labelled “Steady partnership with/without concurrent partners” 
(medium risk). The largest class 3, containing 58% (n= 803) of the women, was labelled “Non-
steady partnerships with many partners”. 
 
Figure 10. Latent class conditional probabilities for men (N=1 436). 
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Figure 11. Latent class conditional probabilities for women (N=1 378). 
 
 
6.1.4 Latent classes associated with repeated chlamydia testing by sex 
In this analysis using proportional odds models, we identified that LCs with high-risk 
sexual behaviour (class 3 and 4) in men were statistically significantly associated with 
increased lifetime repeated testing for chlamydia (Figure 12). Among women, high-risk sexual 
behaviour (class 3) was also statistically significantly associated with increased odds of 
repeated lifetime testing. Additionally, in women, class 3 was also associated with repeated 
testing during the previous 12 months. Among men, we found only a borderline statistical 
association between the high-risk class 3 and repeated testing during the previous 12 months 
(Figure 12). 
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Figure 12. Association between latent class membership and repeated testing by sex, 
adjusted for age groups.  
 
6.1.5 Latent classes associated with repeated chlamydia infection by sex 
With a proportional odds model among men, we found that class 4 had statistically higher 
odds to test positive for current chlamydia infection than class 1 (Figure 13). Class 3 among 
men had borderline statistically significantly increased odds as well. However, for the outcome 
Lifetime repeated chlamydia (never, once, twice or more) in men proportional odds assumption 
was not met, and therefore a multinomial logistic regression model was applied, with no 
assumption on the odds between categories of the outcome. Thus, we identified that men in 
class 3 had 1.84 (95%CI: 1.03–3.26) higher odds of having a lifetime infection once compared 
to never having it (as compared to class 1). Respectively, class 4 had 2.54 (95%CI: 1.39–4.64) 
higher odds to have lifetime chlamydia once compared to never having it as compared to class 
1 (Figure 13). The odds of having chlamydia infection twice or more compared to having had 
it once varied across LCs in men as well, though not statistically significant. 
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Among women, none of the associations were statistically significant for Lifetime 
repeated chlamydia infection or current chlamydia infection (Figure 13). 
 
 
Figure 13. Association between latent class membership and Chlamydia infection by 
sex, adjusted for age groups 
 
6.2 STUDY III 
6.2.1 Characteristics of the study participants 
In this analysis, we included 605 889 chlamydia cases reported during two periods: 
1992–2004 and 2009–2018. During period 2009–2018, 361 330 cases (60% of included cases) 
were reported (Figure 14). Overall, among reported chlamydia cases, 58% were women and 
85% were in the age group 15–29 years. For the analysis for two periods, we included 
9 902 855 persons tested for chlamydia, of those 53% were reported during period 2009–2018. 
During the first period on average 77% of all tests were performed in women, as compared to 
68% in the second period. The available data on the age groups among the tested population 
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during the period 2009–2018 revealed that on average 66% of the tested population were in the 
age group 15–29 years. 
 
 
Figure 14. Reported monthly national incidence rates of chlamydia cases per 100 000 
population in Sweden, 1992 to 2018. Excluded years (2005–2008) are highlighted in grey. 
  
We calculated the proportion of the population (aged 15–64 years) tested annually, which 
was between 5.2% and 6.9% during 1992–2004 and between 7.2% and 8.5% during 2009–
2018. During the first period, the proportion of the population tested annually was similar 
between able-to-detect (5.0–7.1%) and unable-to-detect (5.2–6.8%) groups. During the second 
period, the proportion of population tested was slightly higher, with 7.1–7.7% and 7.2–9.0% in 
each group, respectively.  
 
6.2.2 Times series trends  
We found that the national trend for chlamydia cases follows a U-shape during the period 
1992–2004 (Figure 15A). The incidence declined from the start of the period, reaching the 
lowest IR in 1996, followed by a subsequent increase of 83.7% between 1996 and 2004. The 
second period (2009–2018) began with higher IRs level than at the end of the first period 
(Figure 15B). Initially a stable trend decreased slightly from 2015 and onward. Overall, the 
rates decreased by 19.7% from 2009 to 2018. The trends were statistically significantly 
different between the two periods (P<0.001).  
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We found similar trend patterns by groups of counties as was seen for the national trends 
(Figure 15C-D). Chlamydia IRs were higher in unable-to-detect counties from 1992 to 2001 
(Figure 15C). After 1996, however, the trend in unable-to-detect counties increased at a slower 
rate (by 75%) than in the able-to-detect counties (by 159%) towards 2004, being statistically 
significantly different (P<0.001). Similarly, throughout the second period, the estimated IRs in 
the unable-to-detect group were higher compared to the rates in the able-to-detect group as well 
(Figure 15D). From 2009 to 2018, a decrease of 11.6% in the able-to-detect and of 23.5% in 
the unable-to-detect group was seen, with both trends almost converging towards the end of 
2018. 
 
 
 
Figure 15. Estimated chlamydia trend (monthly IR per 100,000 population), 1992 to 2004 
and 2009 to 2018, for the national chlamydia cases (A and B) and by group of counties (C 
and D). A and B, Solid black line represents national IRs; shaded area represents 95%CIs. C 
and D, Black solid line represents able-to-detect counties; black dashed line represents unable-to-
detect counties. Shaded area represents 95% CIs. 
 
6.2.3 Seasonality  
The national within-year periodicity of chlamydia cases was similar in both periods: the 
highest IRs compared to the annual average of chlamydia IRs were seen in months 9–11 
(autumn), and the lowest IR in month 8 (summer) and month 1 (mid-winter), with the autumn 
peak slightly shifted in the second period (Figure 16). Periodicity was statistically significantly 
different between periods (P<0.001). 
A
 
B
 
C
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Seasonality patterns were identical to the national model, with no statistically significant 
differences found between groups of counties within each period. 
 
Figure 16. Estimated periodicity (monthly Incidence Rate Ratio) from fitted model for 
the national number of chlamydia cases in Sweden, 1992-2004 and 2009-2018. 
 
6.2.4 Association between testing and chlamydia rates 
Based on the annual data, we estimated that an increase in the proportion of the tested 
population (aged 15–64 years) was statistically significantly associated with an increase in 
chlamydia IRs in the first period. However, this effect declined over time (interaction term, 
P<0.019). Hence, for a one percent increase in the proportion of the population tested, we 
estimated an expected 7.0% (95%CI: 4.1%–9.5%) increase in annual chlamydia IRs in 1992, 
but the corresponding annual increase in chlamydia IRs in 2004 was only 2.3% (95%CI: 
0.01%–4.9%) (Figure 17A). Similarly, the predicted effect of increased testing on estimated 
IRs diminished between 1992 and 2004 in each county group. In order to visualize this effect, 
we predicted chlamydia IRs from 1992 to 2004 for a hypothetical increased annual testing 
coverage by 1% for each year. The predicted counterfactual chlamydia IRs were higher 
throughout the period, although with a strongly diminishing increase in chlamydia IRs in the 
able-to-detect group towards 2004 (Figure 17B). For the period of 2009–2018, we did not find 
a statistical association between the proportion of the population tested and chlamydia IR, 
either at the national level or by group of counties. 
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Figure 17. Estimated annual chlamydia incidence rates adjusted for proportion of 
population tested nationally (A) and by group of counties (B), 1992 to 2004. 
Solid black lines represent estimated IRs from the model, grey solid lines represent counterfactual 
IRs with 1% increased proportion of tested populations (A). 
Black solid lines represent able-to-detect counties estimated IRs from the model, grey solid lines 
represent counterfactual IRs with 1% increased proportion of tested populations in able-to-detect 
counties (B). 
Black dashed lines represent unable-to-detect counties estimated IRs from the model, grey dashed 
lines represent counterfactual IRs with 1% increased proportion of tested populations in unable-
to-detect counties (B). 
 
6.3 STUDY IV 
6.3.1 Estimated chlamydia prevalence 
Our model estimated similar patterns of prevalence among women and men: an increase 
between 2009 and 2012, followed by a decrease in 2015 and 2018 (Table 4). Overall chlamydia 
prevalence in the age group 15–29 years was approximately 1.6 times higher in women 
compared to men in all years of the study. 
 
Table 4. Estimated median chlamydia prevalence (in percent) in the age group 15–29 
years among sexually active men and women in Sweden, 2009, 2012, 2015, 2018.  
Year 
Men Women 
Median 
prevalence 95% Credibility interval 
Median 
prevalence 95% Credibility interval 
2009 3.73 2.31–7.67 5.87 5.25–6.61 
2012 3.93 2.27–8.33 6.14 5.45–6.93 
2015 3.36 2.04–7.03 5.29 4.71–5.95 
2018 2.33 1.53–4.55 3.62 3.22–4.06 
A
 
B
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Estimated chlamydia prevalence ranged between 1 and 7 % depending on year, age group 
and sex. The highest chlamydia prevalence was estimated for all years in age group 15–19 
years, followed by the age group 20–24 and 25–29 years (Figure 18) with the exception of 
2009 when the highest prevalence was estimated in men in age group 20–24 years instead. In 
general, we estimated the decline in prevalence between 2009 and 2018 with biggest decline 
seen in all age groups and both sexes between 2015 and 2018. The prevalence in 2015 in 15–
19 year old men was 5.3% (95%CrI: 4.35%–6.29%) and dropped to 3.6% (95%CrI: 2.76%–
4.39%) in 2018, a drop by 32.5%. Among 15–19 year old women respectively, the prevalence 
in 2015 was 5.7% (95%CrI: 5.25%–6.22%) and dropped to 3.7% (95%CrI: 3.38%–4.19%) in 
2018, a drop by 34.6%. Similar percentage drops were estimated in the remaining age groups 
and sexes between 2015 and 2018, which resulted in the lowest prevalence estimates in 2018 
(Figure 18). 
 
 
Figure 18. Estimated chlamydia prevalence among sexually active men and men by age 
groups in Sweden, 2009, 2012, 2015, 2018 (vertical bars represent credibility intervals). 
 
6.3.2 Estimated chlamydia incidence 
The estimated (true) incidence rates were consistently higher compared to the notified 
chlamydia incidence rates in the surveillance system: in the range of 1.6–2.2 times higher in 
men and 1.8-2.9 times higher in women in the population 15–29 years of age (Figure 19; note, 
that for the comparison with notified incidence rates, we recalculated true incidence rates with 
the whole population as denominator). This implies that every year we potentially under-
diagnose between 26 829–56 103 chlamydia cases among women and between 16 626–29 647 
chlamydia cases among men (estimated for 2009, 2012, 2015, and 2018). 
 
 
40 
 
Figure 19. Estimated chlamydia incidence rates (dots with bars) and notified (crosses) 
chlamydia rates per sex and age groups in Sweden, 2009, 2012, 2015, and 2018 
(denominator: total population, including not sexually active population). Vertical bars 
represent 95% credibility intervals. 
 
6.3.3 Estimated proportion of asymptomatic chlamydia cases in the 
population 
We estimated the median proportion of asymptomatic (including undiagnosed chlamydia 
cases) cases to be 83% for men and 88% for women in the general population aged 15-29 years. 
The lower bound of 95%CrI for the proportion of asymptomatic cases was 65% among men 
and 82% among women, while the upper bound reached 95% and 91%, respectively. In 
comparison, the median proportion of notified asymptomatic cases in the surveillance system 
was 70% for men and 76% for women. While the proportion of asymptomatic cases notified 
due to PN was 40% among women and 66% among men (151). 
 
6.3.4 Sensitivity of analysis results  
Sensitivity results revealed that prevalence decreased if the probability of a false positive 
test increased, since then the observed number of cases is partly explained by the higher false 
positives and the true prevalence is lower. Prevalence decreased if the probability of a true 
positive test increased, as tested individuals would be infectious a shorter time. The prevalence 
increased when the proportion of diagnosed cases that were asymptomatic increased. The 
prevalence was unaffected by the spontaneous clearance rate and by time to seeking treatment 
based on symptoms if the values were close to ours (18.7–20.0 days), however, slightly 
increased when longer than 6 months due to the fact that infected individuals stay infectious a 
longer time. 
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The incidence increased when there was an increase in the spontaneous clearance rate 
and increase in of the proportion of diagnosed cases that were asymptomatic. The incidence 
decreased when the probability of a false positive test decreased and the probability of a true 
positive test increased, since infected individuals are infectious a shorter time. The incidence 
was unaffected by the symptomatic treatment seeking rate. 
The probability of an incident case to be asymptomatic decreased with an increased 
probability of a false positive test. This probability of an incident case to be asymptomatic 
increased the probability of a true positive test; and increased if the proportion of diagnosed 
cases that were asymptomatic increased. 
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7 DISCUSSION 
In the studies included in this thesis, we identified risk factors for chlamydia infection 
and risk behaviour patterns associated with repeated testing. We also concluded that chlamydia 
notification rates were driven by testing during 1992-2004, but not during 2009-2018. Finally, 
we estimated a decline in chlamydia prevalence between 2009 and 2018, which supported our 
hypothesis on the reason for the declining observed chlamydia rates. Below I discuss our 
findings and acknowledge the strengths and limitations of our studies. 
 
7.1 INTERPRETATION AND IMPLICATIONS 
7.1.1 RISK FACTORS 
In studies I-II, we used data from a large cohort study from an urban STI clinic. We 
identified and updated the knowledge on independent risk factors associated with chlamydia 
diagnosis in study I. The identified independent risk factors, such as being young, reporting 
more than 6 sexual partners during the previous 12 months, reporting sexual activity involving 
oral/vaginal/anal contact, consuming alcohol before sex, testing due to partner notification, and 
having symptoms were consistent with risk factors reported in previous studies within and 
outside Sweden (77-79, 83, 84, 221). Although we could not confirm the association between 
condom non-use with casual partners and chlamydia infection, other studies have reported that 
consistent use of (male) condoms are effective in preventing chlamydia (222, 223) and other 
STIs (224). Previously identified risk factors for chlamydia were utilized elsewhere to develop 
algorithms to support selective screening (225-227). The presented prediction models provided 
prognostic accuracy in separating test positive and test negative individuals, suggesting it could 
facilitate selective chlamydia screening even at the population level (93). However, several 
other studies reported failure to identify accurate screening algorithms with suggested 
underlying reasons (228, 229), which need further investigation and evaluation.  
In study II, based on sexual behaviour and substance use, we found distinct latent classes 
consisting of patterns ranging from low- to high-risk behaviour. Among men with high-risk 
behaviour, we could specifically distinguish between condom users and non-users. In high-risk 
behaviour LC in women, however, only one class was identified, with 33% who never or 
seldom used condoms. Previous studies have reported that even when respondents consider it 
important to use condoms and intend to use them, the actual use varies by type of partner and 
type of sexual contact (230-234). In Sweden, hormonal contraceptives have been the first 
choice of contraception over the past decades as respondents stated more concern regarding 
unwanted pregnancy than prevention of STIs, and thus condom use has not been a priority 
(122, 235, 236). The latest data also suggested that condom use has decreased over time 
between 2007 and 2013 among 15-24 year old individuals in Sweden (236).  
Additionally, we found a high prevalence of alcohol consumption in moderate- and high-
risk behaviour LCs. Previous studies reported that alcohol consumption in close proximity to 
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the sexual encounter could contribute to sexual risk-taking due to poor judgement on the choice 
of casual sexual partner, multiple sexual partners, increased probability of condomless sex, and 
therefore increase in the risk of chlamydia acquisition (237-240). Furthermore, in our high-risk 
classes, we identified combined substance use (alcohol and drugs), which is also reported 
previously to be linked to increased sexual risk-taking behaviour (90, 237). Sexual risk-taking 
is a complex topic, where other researchers have studied personality characteristics (241, 242) 
besides the variables included in our latent class membership (such as sexual behaviour and 
substance use), which can further identify subgroups with greater need for prevention. 
The results from study II showed that women and men in high-risk behaviour LCs had 
higher odds to test repeatedly for chlamydia during their lifetime. Furthermore, women in the 
high-risk behaviour class had higher odds to test repeatedly for chlamydia during the previous 
12 months, but no such association was found in men. This suggests that current efforts to 
promote testing are adopted by individuals in high-risk behaviour classes, both women and 
men (189). Generally, men are under-represented among the chlamydia tested population, thus 
in Sweden, only 30% of all tests are performed in men (32). Of all tests over 20% are from 
internet-based services, where the number of tests in men, however, increased by 71% between 
2013 and 2017 (156). Adolescents and young adults are at higher risk for chlamydia (due to 
multiple sexual partnerships and casual sexual contacts) and therefore, re-testing of chlamydia 
positive individuals is recommended with varying intervals (3-12 months) (33, 165). Evidence 
suggests that repeated testing after the initial infection is beneficial, since a high proportion of 
repeat chlamydia infections can be found (102, 104, 243-245), and therefore further 
transmission can be prevented. Thus, repeated testing for chlamydia is commonly reported 
elsewhere (246-248).  
In study II, we found that men in the high-risk behaviour class 4 were more likely to test 
positive for chlamydia twice or more times during their lifetime, however with borderline 
significance. This finding may indicate that no change in sexual behaviour occurred for these 
repeatedly tested men over time. Similar findings were reported in previous studies where LCs 
of high risk-takers were more likely to contract STIs (249-252). As described above, condom 
use with casual partners in high-risk behaviour classes was low or moderately low; indicating 
that promotion of condom use should be reinforced. However, effective communication to 
reach the population at risk with safe sex messages is still under research (253, 254). 
 
7.1.2 INCIDENCE TRENDS AND PREVALENCE 
In studies III and IV, we utilized data on notified chlamydia cases and testing for 
chlamydia. We found that chlamydia notification rates at the national level and by county 
groups (able- and unable-to-detect nvCT) during the period 1992–2004 had a U-shaped trend, 
with several proposed reasons for such a trend. Initially, the decrease in the late 1980s and early 
1990s was thought to be attributable to fear for the emergence of HIV infection and following 
prevention campaigns (40, 255, 256). This affected also trends of other STIs in Sweden and 
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elsewhere: gonorrhoea rates declined by 40–70% in most western EU countries, as did syphilis 
rates, a decline by 10–60% (257). After a relatively short plateau, chlamydia and other STIs 
(gonorrhoea and syphilis) notification rates started to rise from the mid-1990s and onward. 
Possible reasons for the rise elsewhere and in Sweden were suggested as follows: the 
introduction of more sensitive diagnostic methods (NAAT), possibly increased chlamydia 
prevalence in the population, as well as a switch to chlamydia high-prevalence target groups 
for testing (44-47). The introduction of antiretroviral therapy for HIV was also considered to 
contribute to that rise (258), as sexual risk-taking was reported to increase as well, such as a 
decline in condom use (259). Another suggested reason for the rising trends is a hypothesis of 
arrested immunity (260). The theory suggests that treatment for chlamydia interrupts the 
development of natural immunity, therefore making individuals susceptible to re-infection. 
This was supported by the findings in studies elsewhere, reporting that an increase in the 
chlamydia rates is actually seen due to repeated infections (261, 262).  
The discovery of a new variant of chlamydia (nvCT) in 2006 (52) affected notified 
chlamydia rates in Sweden primarily because of false-negative test results (56, 263). In 
addition, our analysis by county groups (able- and unable-to-detect nvCT) showed that the 
trends of chlamydia notification rates differed already by county type from 1992 through 2004 
(pre-nvCT). The possible differences may lie in varying testing coverage, which we describe 
below. Additionally, possible differences in the organization of partner notification process 
(centralized versus decentralized) (181, 183), varying success in reaching identified partners of 
index cases (264), and varying investments in primary and secondary prevention (265) could 
explain these differences between counties. Following the U-shape pattern as it was seen at the 
national level, trends have increased at the different rate already since 1998 depending on 
county type. The emerged nvCT cannot fully explain the differences in the observed increase 
because the estimated emergence of nvCT was in 2002-2003, with a gradual spread (54). The 
role that nvCT had on the chlamydia trends after its discovery was the reinforcement of control 
measures, with intensified testing efforts and partner notification. In the second analysis period 
(2009-2018), chlamydia rates declined consistently in both types of counties, although again at 
a different pace. The proportion of nvCT among all cases dropped to 5% in both types of 
counties towards 2015 (57), as compared to as high as 64% in unable-to-detect and as high as 
19% in able-to-detect counties in 2007 (55). With nvCT being under control and unable to 
affect chlamydia trends in the latter study period, we suggest that chlamydia notification rates 
could have been affected by testing volumes which we investigated further in our study. 
Moreover, in study IV, we estimated true incidence rates to be 2 to 3 times higher than 
notified rates between 2009 and 2018, which is anticipated, since chlamydia infection is often 
asymptomatic (as was also estimated in our study), and therefore not all cases are identified 
(266). Due to slow natural clearance (69, 74, 76), if not tested and treated, asymptomatic 
chlamydia-infected individuals can contribute to the ongoing transmission and fuel the 
epidemic. In fact, it was reported that antibodies for past chlamydia infection could be found 
in a third of 16–24 year old individuals who never previously had been tested for chlamydia 
(171), which in turn, can potentially contribute to the development of sequelae (2, 3, 267). 
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Therefore effective approaches to screening (179) should be researched further, especially in 
light of vague evidence of the effectiveness of opportunistic testing (opportunistic screening) 
(268), which is in place in Sweden. Furthermore, special attention should be dedicated to men’s 
screening since their test-seeking behaviour is less successful (119, 120, 156, 247). 
In study III, we studied the role of testing as one of the possible contributors to the change 
in the national notification trends over time, and possible underlying reasons for chlamydia 
rates being different between two types of counties (able- and unable-to-detect nvCT at the 
time). We found that increasing testing levels were associated with an increase in chlamydia 
notification rates during 1992–2004 but not during 2009–2018. Previous studies reported a 
strong relationship between increasing testing rates and increasing notified chlamydia rates (42, 
46, 269-271), including repeat testing after the previous positive test (100, 248). Since the mid-
1990s, many efforts were made to expand opportunistic testing in Sweden by offering testing 
at outpatient clinics (including drop-in), and since the early 2000s self-sampling at home and 
sample analysis at the laboratory, at no cost (156, 272). In the first period, increasing notified 
chlamydia IRs were dependent on the increasing testing coverage, suggesting likely 
underestimation of the true incidence rates, and more likely reflecting improvement in the 
diagnostic, reporting, and testing coverage (273). A similar influence of time-varying biases on 
the notified case rates was reported elsewhere (51). In the second period, however, our results 
suggest that notified chlamydia IRs is no longer driven by the testing volumes in the population 
targeted for testing as it was in the first period. Thus, notified chlamydia IRs more reliably 
mirror true incidence rates in the second period and possibly indicate a true decline in 
chlamydia incidence rates, which we investigated in study IV. 
We investigated several possible reasons for the observed decline in chlamydia 
notification rates during 2009–2018. First, we looked at a possible change in the profile of the 
tested population (demographics) as was reported elsewhere (270). Available limited data 
suggests that no major changes occurred in terms of the distribution of the tested population by 
sex and age groups: two-thirds of women and the same proportion of individuals aged 15–29 
years were among the tested population annually. Subsequently, in study IV, we investigated 
whether the decline in chlamydia prevalence could be the reason for the decreasing notified 
chlamydia rates seen in Sweden during 2009–2018. Indeed, we estimated a decline in 
chlamydia prevalence in 15–29 year old individuals during that period, with the biggest drop 
(at least 30%) in prevalence seen between 2015 and 2018 in all age groups and both sexes. 
When the duration of the infection is reduced, the prevalence is being reduced as well, and as 
a result, the transmission of the infection is abridged, which indicates the success of the 
screening program (274). From the point of the hypothesis of the dynamic topology of STIs 
epidemics (66), we suggest that the chlamydia epidemic evolved through time and potentially 
reached the decline phase because of prevention and control measures, by faster identification 
of the infected individuals, treatment, and PN, thus reducing the duration of the infection. 
Estimated prevalence by age group and sex in our study were consistent with population-based 
estimates obtained through various methods in the UK (84), the Netherlands (116), Norway 
(79), France (115), and other European and high-income countries (1, 117, 118). However, 
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prevalence is closely related to the population being tested, and consequently depends on sexual 
networks and core groups coverage (105, 273), which we did not consider in our modelling 
study.  
Partner notification is an important component of chlamydia control strategy in Sweden, 
and therefore we included it in the model in study IV within screening rate for both chlamydia 
positive and negative individuals. In our surveillance data, most infected asymptomatic men 
were identified through PN (on average, 70% during the study years), while only 16% were 
identified through the screening (average during the study years) (151). This indicates that these 
men would be missed if PN would not include them. In the surveillance system, on average 
40% of asymptomatic women are identified through PN and 30% via screening (average during 
the study years) (151). However, in our study we could not estimate the individual contribution 
of control measures on the prevalence. Previous modelling studies suggest that increased 
effectiveness of PN could be as effective in reducing chlamydia prevalence as increasing 
screening coverage (178, 179, 275). Partner notification is also effective in reducing the 
chlamydia burden at the population level and decreasing re-infection at the individual level 
(178, 276, 277). By including information on PN in our model in the screening rate for both 
chlamydia positive and negative individuals, we achieved a more realistic model for Swedish 
conditions and improved the precision of outcome estimates.  
Generally, understanding the effectiveness of screening on chlamydia prevalence comes 
from modelling studies (178, 275, 278-280), Meanwhile, randomised and non-randomised 
controlled trials indicate uncertainty regarding the effect of screening on the prevalence, while 
moderate-quality evidence exists regarding the effect of chlamydia screening on the incidence 
of PID and chlamydia reinfection (159). Furthermore, to our knowledge, opportunistic testing 
(opportunistic screening) has never been evaluated elsewhere, while several countries 
continued to scale up their testing for chlamydia (154). Besides the potential benefits of the 
screening, some concerns were also reported. It was argued that screening programs for 
chlamydia in a low-risk population could be hampered because the majority of tested 
individuals would be tested negative and therefore might change their sexual behaviour 
towards riskier (281). This was supported in several studies reporting that repeated testing may 
facilitate only short-term change in high-risk behaviour if an individual was tested positive for 
chlamydia (282, 283), and those tested negative may change towards more risky behaviour 
(281) (284), suggesting unintended consequences of the testing (285-287). Additionally, the 
arrested immunity hypothesis suggests that individuals are susceptible to chlamydia after 
treatment due to interrupted development of natural immunity (260). This puts individuals at 
risk for repeated infections, suggesting potential harm of the screening, especially in the 
countries where partner notification (PN) is not part of the case management (136). It has to be 
said that the potential harm of screening for chlamydia has never been evaluated either (159).  
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7.2 STRENGTHS  
A core strength of studies I and II is their large sample size: we were able to recruit almost 
3 000 individuals, who answered the questionnaire and provided a biological sample. To 
promote unbiased answers, the questionnaire was provided to the study participants before the 
sampling for chlamydia, so that the study participants were unaware of their chlamydia status 
when answering, thus, minimizing the social desirability bias. Even though the overall 
missingness in the questionnaire data was comparatively low, we still choose to use a multiple 
imputation approach in study I in order to increase the power and provide valid inference (206). 
Additionally, the laboratory verification of the chlamydia status (as opposed to self-reported 
status) ensured unbiased ascertainment of the outcome.  
Study II is, to our knowledge, the first study to investigate the association between sexual 
risk behaviour patterns and repeated testing. The latent class analysis approach allowed us to 
identify a range of behavioural patterns as well as sub-groups of individuals at higher risk for 
repeated chlamydia testing. Thus, providing information for future prevention and control 
measures. 
A key strength of studies III and IV is the use of high-quality national surveillance data, 
which has been formally evaluated according to the guidelines of the Centers for Disease 
Control and Prevention (288). The Swedish chlamydia surveillance system that was used to 
generate this data has previously been described as useful, timely, and accurate (147). Another 
strength was the length of follow-up that allowed the use of a 23-years long series of data on 
chlamydia cases and testing, comprising a total of 606 000 cases and nearly 9.9 million tests 
for chlamydia.  
A specific strength of study IV was the availability of partner notification information, 
allowing us to adjust our model to the Swedish context. The addition of the PN parameter was 
vital, as the distribution of asymptomatic chlamydia cases in Sweden differs substantially by 
testing reason (partner notification vs. screening). Our model also distinguishes between testing 
in the absence or presence of symptoms, by assigning different rates. Additionally, we also 
extended the original model by introducing different transition rates for those who tested 
negative and positive for chlamydia (114). We believe that this refinement of the model also 
improved the precision of our estimates. 
 
7.3 METHODOLOGICAL CHALLENGES 
After a study is conducted, it is crucial to assess to what degree the results are an 
accurate representation of the underlying truth, and whether and to what degree chance, 
potential biases, or the study design may have played a role. Below I discuss the 
methodological challenges encountered during the entire research project. 
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7.3.1 Study design 
7.3.1.1 Cohort study 
Cohort design is a type of observational study design where a cohort of individuals 
characterized by some common characteristic (e.g. individuals born in a particular year) is 
followed-up to an observed outcome of interest. Disadvantages of cohort studies are that they 
are time- and resource-consuming (289). In studies I and II, we utilized data from a prospective 
cohort of visitors of an STI-clinic recruited at the visit for chlamydia testing (107). The goal of 
initial studies was to measure chlamydia infection and associated behaviours at the inclusion 
and follow-up, and establish the risk factors for repeated infection at the follow-up (107). 
Regrettably, 44% (1 063/ 2 418) of the initial cohort did not return for a follow-up visit, which 
represents one of the paramount biases in prospective cohort studies, loss to follow-up 
(selection bias) (289). This bias and insufficient sample size prevented us to use the follow-up 
data. Therefore, we only utilized the data at the inclusion and analysed it as a cross-sectional 
cohort. We also performed a drop-out analysis, and found that married/cohabitated individuals, 
seldom tested for chlamydia during their lifetime, and those tested negative for chlamydia at 
the inclusion did drop out more often at follow-up (206). 
 
7.3.1.2 Mathematical modelling study 
In Study IV, we applied a basic deterministic model, which considered surveillance data, 
natural history, and health care-seeking behaviour. We obtained population estimates for 
averaged sexual risk behaviour across age groups and sex. With additional data on different 
levels of sexual risk behaviour and partnerships, it would have been possible to increase the 
model complexity with further parameterisation. Another limitation of the model is that it is 
not suitable for forecasting, thus we cannot study the impact of individual (or combined) 
control measures (such as PN) on incidence rates and prevalence.  
 
7.3.2 The role of bias  
It is important to consider to what degree systematic error (bias) has influenced results 
during the design, conduct, and analysis of the study. Several potential biases may arise in our 
research and are described below. 
7.3.2.1 Participation bias  
Participation bias (non-response bias) can arise when some factor affects which 
individuals participate in the study. In studies I and II, we utilized data from an STI clinic, 
where volunteer bias could arise if individuals accepting to participate in the study are in 
some way different from those who do not. In sexuality research, it has been reported that 
individuals accepting participation in a study have in general a more open attitude towards 
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sexuality, and are more sexually experienced compared to those who chose not to participate 
(290, 291).  
 
7.3.2.2 Information (measurement) bias: Social desirability bias 
In studies I and II (partly in Study IV), we used data on self-reported sexual behaviour, 
which is a sensitive topic. Evidence suggests that respondents in the research of sexuality and 
sexual behaviour are prone to report socially acceptable behaviour due to expected gender 
norms in society (292). This in turn can distort the association between inaccurately reported 
sexual behaviour and the outcome of interest. It is commonly reported that men report more 
sexual partners than women (293-295), not only due to the social desirability bias, but also 
due to the different reporting techniques applied: estimating vs. counting sexual partners 
(293). In our study, the median number of sexual partners during the previous 12 months did 
not differ by sex, although the range of sexual partners was higher for men than women. 
Additionally, we found that the number of casual sexual partners during the previous 12 
months was slightly higher for men than for women (120). 
 
7.3.2.3 Recall bias 
In studies I and II, we used behaviour data, which respondents reported retrospectively 
for 6 months, 12 months and a lifetime. General recall bias can take place since study 
respondents may recall past events or experiences differently in terms of accuracy and 
completeness (296). Recall bias can also be differential if respondents recall their exposure 
“better” based on the outcome of the test (i.e. individuals may try harder to remember if they 
have a disease) (297). Overall, underreporting or inaccurate reporting of past behaviour is 
reported for longer recall periods as compared to the ones close in time (298, 299). This can 
lead to underreporting or missing data. However, in our study I and II, the questionnaire was 
distributed before obtaining the result on chlamydia status, therefore recall bias should not 
be differential.  
 
7.3.2.4 Item response bias  
This type of bias is characterized by respondents refusing to answer a particular 
question or set of questions. Sexual behaviour and substance use are reported as sensitive 
topics, and therefore item non-response is a possible consequence of it (125, 300). There is 
strong evidence that computer-assisted interviews can decrease item non-response to 
sensitive topics as compared to self-administered questionnaires or face-to-face interviews 
(301). In studies I and II, we used a self-administered paper questionnaire, where we aimed 
to minimize this bias by piloting the questionnaire on a suitable population and consequently 
adjusting the design of the questionnaire. Despite of this, we experienced missing values for 
some of the questions. This was handled by using multiple imputations (302). We also 
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performed item non-response analysis, where we found that the missing answers were 
concentrated on questions asking about the number of partners, the reason for testing, and 
the use of condoms with casual partners (206). 
 
7.3.2.5 Bias due to assumptions in the model 
In study III, we selected a limited number of manifest (observed) variables to identify 
latent classes. We believe that the sample size of our study was sufficiently large, and that we 
selected accurate high-quality manifest variables, i.e.variables predicting latent variables with 
a probability near one or zero, to identify these latent classes. However, as discussed elsewhere, 
it is possible to increase the number of possible patterns, which would be missed otherwise due 
to their rarity, by adding extra observed variables (303). 
In study IV, we make a number of assumptions in the model regarding the distribution 
of the parameters and the data. We also had to rely on the existing incomplete knowledge on 
the natural history of chlamydia (304, 305), which could affect the outcome of the model. 
However, we performed extensive sensitivity analyses (as described in Material and Methods), 
and were able to identify the parameters that our modelling outcomes were either sensitive to 
or robust for. 
 
7.3.3 Confounding 
When an association between exposure (independent variable) and outcome (dependent 
variable) is estimated, it is important to assess whether a third variable can influence (distort) 
this relationship. The third variable here is a confounder if it is causally related both to the 
exposure and to the outcome: importantly, a confounder is not part of the causal pathway 
between exposure and outcome (306). Typical examples for confounders in epidemiological 
research are age and sex. It is possible to control for confounding at the design stage, by 
randomization, restriction, or matching (306). At the analysis stage, stratified analysis and 
multivariate analysis (regression adjustment) are possible solutions to control for confounding 
variables (306).  
We had to control for age and sex in our studies at the analysis stage. In study I, we were 
applying directed acyclic graphs using a web application to visualize assumptions about 
confounding variables (307). This method helped us to minimize the bias in further multivariate 
regression, if the directed acyclic graphs we created is correct. In study II, we performed the 
stratified analysis by sex and adjusted for the age groups in the analysis of associations between 
latent classes and outcomes. In study III, the age and sex could be potential confounders when 
comparing the differences between the types of counties due to possible shift in age and sex 
composition of tested populations over time. However, available data for the period 2009-2018 
suggests that age and sex distribution among the tested population did not change. In study IV, 
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we modelled the outcomes by stratifying by sex and age groups as some of the input parameters 
and the data could be confounded.  
 
7.3.4 Generalizability 
Generalizing the results from study I and II to the broader population requires care, as 
our study respondents were recruited at an STI clinic. It has been reported previously that a 
higher proportion of individuals with high-risk behaviour will be represented among the typical 
visitors of an STI clinic (241, 249, 308). We are potentially limited in generalizing results from 
our study III to countries other than Sweden. Although, it is possible that our results on 
chlamydia trends and associations can apply to countries with a similar healthcare system, and 
similar chlamydia epidemiology and control measures. Results from study IV were robust and 
can be generalized to other high-income countries of similar sexual behaviour in the population.  
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8 CONCLUSIONS 
 
Studies I and II: 
 Identified independent risk factors for incident chlamydia infection were consistent with 
published evidence within and outside Sweden. 
 Individuals in latent classes of high-risk sexual behaviour are more likely to test repeatedly for 
chlamydia during their lifetime, suggesting that they complied with prevention messages 
aimed to increase testing after unprotected sexual contact with new or casual partners. 
 Identified independent risk factors and high-risk sexual behaviour latent classes indicate the 
practice of unsafe sex, endorsing the need for enhanced promotion of safer sex and testing. 
 
Studies III and IV: 
 Chlamydia notification rates in Sweden followed the shape observed in other high-income 
countries during 1992–2004. However, Sweden stands out from other countries by having 
decreasing trends of chlamydia notification rates during 2009–2018. 
 Chlamydia notification rates were not driven by testing during 2009–2018, as they were during 
1992–2004. This suggests less biased notified chlamydia IRs, mirroring true incidence rates 
during the period 2009–2018.  
 Estimated chlamydia prevalence was in line with prevalence in other high-income countries 
for both men and women. 
 Estimated chlamydia prevalence declined during 2009–2018, supporting the hypothesis on 
being the reason for the declining observed chlamydia rates. 
 The estimated high proportion of undiagnosed asymptomatic chlamydia cases is likely to 
contribute to the ongoing transmission of chlamydia. Thus, testing for chlamydia should 
expand to reach more asymptomatic individuals. 
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9 SUGGESTIONS FOR FUTURE RESEARCH 
This thesis addressed several research questions, which were of relevance specifically to 
Sweden, but could be also applicable for other countries. However, several blind spots remain 
to be addressed. 
With study I, we have contributed to the accumulated knowledge on factors associated 
with chlamydia. To our regret, we were unable to study sexual behaviour factors associated 
with repeated chlamydia infection due to the small sample size. Thus, this merits further study 
to inform Swedish-specific control measures and interventions. 
Our study III revealed that we still do not know enough about the population tested for 
chlamydia. We attempted to answer this question with study II, however, visitors to an STI 
clinic are not entirely suitable to draw conclusions on the general population. Future research 
should focus on studying behavioural factors, including the reason for testing, among the 
general population or the population attending different types of health care services. The 
results would allow determining whether relevant subgroups at risk are being reached. 
Opportunistic testing is the approach employed in Sweden, however, it has not been 
formally evaluated. Therefore, a study to evaluate the effectiveness of opportunistic testing on 
chlamydia prevalence reduction and prevention of sequelae from chlamydia infections is 
warranted, also in light of existing limited evidence internationally (157-159). With the current 
increasing number of tests annually, case management, and PN, the control strategy in Sweden 
should also be evaluated in terms of costs as was done elsewhere, for instance in the USA 
(309). The most recent estimation of costs in Sweden was in 2010 for the PN work alone and 
yielded 5.6 million EUR per year, resulting in PN costs of 150 EUR per one chlamydia case 
(310). Such evaluations are essential for the planning of resources.  
Study IV estimated a large number of undiagnosed (including asymptomatic) chlamydia 
cases in the population, but there is still little understanding of effective ways to reach the 
asymptomatic infected individuals with testing. Thus, research should target this area to 
develop user-acceptable and feasible testing approaches. For instance, some research showed 
promising results in school or university-based testing programmes (311). Furthermore, men 
should be of particular focus due to their poorer test-seeking behaviour (156, 247). 
Moreover, our results suggest the need for the promotion of safe sex. Future research 
should look into the most effective ways to target persons at risk at the population level and 
individual level. Population-based interventions via modern technology and social media is a 
popular approach that can reach a large amount of target population. However, the 
effectiveness and sustainability of such interventions on sexual risk-behaviour change could be 
limited (312, 313) and should be explored further. Based on the results from study II, more 
tailored prevention strategies should be explored based on the sex and risk-behaviour profile 
of individuals. Effective and long-lasting population-based and individual-based interventions 
reaching specific subgroups should be studied further as current evidence suggest that their 
effect could be weak and with limited length (312-314). Additionally, further research should 
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be encouraged to explore how individuals apply current chlamydia prevention strategies, e.g. 
practising both testing and condom use, or favouring one over the other.  
While modelling studies can provide estimates on the outcome of interest, such as 
prevalence, other study types should be considered in Sweden as well. Future studies to 
estimate chlamydia prevalence could be carried out on a random sample of the population and 
using existing knowledge-attitude-behaviour questionnaires together with biological sampling 
for chlamydia. Such methodology successfully is applied in the UK (National Surveys of 
Attitudes and Sexual Lifestyles (NATSAL)) and the USA (National Health and the Nutrition 
Examination Survey (NHANES)) (94, 315).  
Studies III and IV indicated that it is warranted to further investigate what components 
of chlamydia control strategy in Sweden affect chlamydia incidence and prevalence. Modelling 
studies could help answer those questions and develop a greater understanding of the role of 
different components, such as partner notification, which can inform future control strategies. 
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10 SAMMANFATTNING PÅ SVENSKA 
Klamydiainfektion orsakas av bakterien Chlamydia trachomatis och är den vanligaste 
sexuellt överförbara infektionen (STI) i världen. Varje år tillkommer uppskattningsvis 127 
miljoner nya fall världen över. På grund av infektionens asymptomatiska karaktär kan 
individer bära den länge och överföra infektionen utan att veta om det. Obehandlad klamydia 
kan leda till allvarliga följder på den reproduktiva hälsan, såsom äggledarinflammation, som 
vidare kan leda till utomkvedshavandeskap och infertilitet. Klamydiainfektion kan tidigt 
upptäckas via testning (opportunistisk screening), behandlas och smittspåras för att förhindra 
vidare överföring.  
Syftet i denna avhandling var att få utökad förståelse för klamydiaepidemiologin på 
individ- och befolkningsnivå i Sverige. Avhandlingen baseras på data från en kohortstudie 
från en STI-mottagning, samt antal klamydiafall och antal testade personer som 
rapporterades till det nationella registret av smittsamma sjukdomar, SmiNet-2, på 
Folkhälsomyndigheten. Vi har använt oss av olika metoder för att svara på våra studiefrågor. 
I studierna I och II använde vi data från en kohortstudie. I studie I fann vi att de som är 20-
24 år unga, haft mer än sex sexpartners under de senaste 12 månaderna, använder alkohol 
före sexakten, rapporterar alla typer av sexuella aktiviteter under den senaste sexuella 
kontakten samt testar sig på grund av smittspårning, var samtliga oberoende faktorer som 
löper statistiskt signifikant ökad risk för att testa positivt för klamydia. I studie II identifierade 
vi fyra latenta klasser (individgrupper) av beteendemönster bland män respektive tre klasser 
bland kvinnor. De latenta klasserna som karaktäriseras av hög risk sexuellt beteende hade 
statistiskt signifikant ökade tvåfaldiga odds för livstids upprepade testning för klamydia, både 
hos män och kvinnor. Kvinnor med hög risk sexuellt beteende hade också ökat tvåfaldiga 
odds för att låta testa sig upprepade gånger under föregående 12 månader. Detta indikerar att 
individer med högre risk för klamydia efterlevde folkhälsorekommendationer om att testa sig 
om det finns risk för infektion. I studie III använde vi tidsserieanalyser för att undersöka 
underliggande komponenter såsom tidstrender och säsongsvariationer. Vi undersökte hur de 
komponenterna förändrades över tid genom att jämföra två perioder: före och efter 
upptäckten av en ny variant av Chlamydia trachomatis i Sverige. Vi analyserade data 
nationellt och i två olika typer av län som vi grupperade efter deras förmåga att identifiera 
den nya varianten. Vi justerade också klamydiaincidens för testningsvolymerna. Vi fann att 
klamydia incidenstrenderna ökade sedan mitten av 1990-talet fram till 2004, liksom 
testningen ökade, vilket tyder på att ökningen av antalet fall kunde kopplas till den ökade 
testningen. Å andra sidan minskade klamydia incidenstrenderna under 2009-2018, trots 
ökade testningsvolymer, vilket tyder på att antalet upptäckta klamydiafall inte drevs av 
testningen, och troligen återspeglar den sanna klamydiaincidensen i befolkningen. I studie 
IV fortsatte vi att utforska orsaken till de minskande klamydiatrenderna (2009-2018) genom 
att uppskatta klamydiaprevalensen med hjälp av matematisk modellering. Vi uppskattade en 
minskning av klamydiaprevalensen bland 15-29 år gamla män och kvinnor under denna 
period, vilket stödde vår hypotes om orsaken till minskade incidens under samma tidsperiod.  
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Sammanfattningsvis är oberoende riskfaktorer för klamydia-diagnos i linje med 
tidigare publicerade studier. Dessutom tyder våra resultat på att grupper av individer med 
hög risk sexuellt beteende är mer benägna att testa sig upprepade gånger för klamydia, vilket 
tyder på att rekommendationer om testning efterföljts särskilt i denna grupp. Tillika 
påverkades inte klamydiatrender av testningsintensiteten under 2009-2018, vilket tyder på en 
sann minskning av klamydiaincidensen i befolkningen. Genom att uppskatta minskningen av 
klamydiaprevalensen i klamydia mest utsatta åldersgruppen 15-29 år under denna period 
kunde vi föreslå orsaken till rapporterade sjunkande klamydia incidens. Preventivt arbete bör 
fortsätta för att nå symptomfria individer med testning och informationskampanjer. 
Ytterligare studier bör undersöka rollen som andra komponenter i klamydiakontrollstrategin 
har för att urskilja deras effekter på klamydia incidens samt planera möjliga förändringar i 
framtida preventiva insatser.  
 
Nyckelord: klamydiainfektion, epidemiologi, risk faktorer, incidenstalet, 
opportunistisk testning, upprepade testning, prevalens, matematisk modell, tidsserieanalys, 
latent klassanalys, regressionsanalys. 
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